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ABSTRACT OF THE DISSERTATION
Elucidation of Emergent Regional Mechanisms of Heart Muscle Dysfunction in the Mouse
Model of Duchenne Muscular Dystrophy
By
Ya-Jian Cheng
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2014
Professor Samuel Wickline, Chair

Cardiac dysfunction is a primary cause of mortality in Duchenne Muscular Dystrophy (DMD),
potentially related to elevated cytosolic calcium. However, the regional versus global functional
consequences of cellular calcium mishandling have not been defined in the whole heart. Here, we
elucidate, for the first time, loci- and age-dependencies between calcium mishandling and myocardial
sheet function as a manifestation of dystrophin-deficient cardiomyopathy. We also map calcium transients
to illustrate the regional dependence of ion flux disturbances in the dystrophin-deficient (mdx) mouse
heart. Furthermore, we elucidate abnormalities in autophagic processes that can be corrected with
nanoparticle therapeutics delivering rapamycin to heart tissues to improve ventricular function in affected
older mice with incipient cardiomyopathy. We conclude that the rapid reversibility of functional defects
by reducing cytosolic calcium or by impacting impaired autophagy points to the significance of regional
mechanical factors in the progression of the disease.

xii

Chapter 1: Introduction

1.1. Duchenne Muscular Dystrophy
1.1.1. The Gene
Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disease that affects
1:3500 of newborn boys who manifest unremitting deterioration of all muscle groups over time.
The symptoms appear at the age of 2–6 years. By the age of 10, untreated patients are usually
wheelchair-bound, and in their 20s they typically succumb (Fairclough, Wood et al. 2013).
The cause of DMD is the near or complete absence of dystrophin protein. The dytrophin
gene is located on chromosome X and is 2.3 million base pair (bp) long (Altamirano, Lopez et al.
2012), occupying ~0.08% of the human genome of 2.9 billion bp (Alloatti, Gallo et al. 1995). It
is the longest known human gene (Table 1). The 79 dystrophin exons are spliced into a 14 kbp
mRNA1, which requires 16 hours for processing in cultured myogenic cells (Altamirano, Lopez
et al. 2012). Although gene therapy has been suggested as a possible cure for the disease, the
large size of dystrophin gene exceeds the packaging capacity of currently available viral vectors.
Although micro-dystrophin (~30% of original dystrophin cDNA sequence) and Dp71 isoform
(~16% length or full dystrophin) were used to tackle the transfection capacity limitation, the
effectiveness for this particularly large gene is yet not proven (Nicolas-Metral, Raddatz et al.
2001; Hecht, Adams et al. 2011; Spurney 2011). Moreover, immune reactions against the
transfected gene challenge the clinical application of gene therapy (Berry, Andruszkiewicz et al.
2013).

1

A gene contains exon(s) and usually intron(s). Exons are encoded into mRNA while introns are removed by RNA
splicing.

1

Histone H1a

Dystrophin

Titin

DNA length

781 bp

2

293 k bp2

mRNA length

781 bp

14 k bp

80

k bp2

Protein M.W.

22 k Da3

427 k Da4

3

M Da5

M bp

Table 1. Example of sizes of genes and proteins in the human genome. Histone H1a is small and
contains no intron. In the human genome, dystrophin is the largest gene, most of which
comprises introns. The titin gene produces the largest single protein in human genome.

Interestingly, both titin, the largest mammalian protein (Han, Grounds et al. 2006), and
dystrophin, the longest gene in humans, exert a significant mechanical role in the heart. Titin is
considered a mechanical spring responsible for diastolic recoil. The size might reflect the
mechanical load it bears. Dystrophin is an adaptor between extracellular matrix and cytoskeleton.
Its gene length reflects the fact that it produces many isoforms, which require alternative splicing
and regulatory functioning of introns. When promoter defects or nonsense mutations,
duplications, and deletions lead to complete absence of dystrophin, the resultant disease is DMD.
When in-frame deletions or other mutations lead to low expression or low function of dystrophin
protein, the resultant disease is Becker muscular dystrophy (BMD), a milder form of DMD
(Bowles, McPhee et al. 2012). Figure 1 illustrates the spectrum of mutations and phenotypes for
the dystrophin gene.

2

Franco-Obregon, A. and J. B. Lansman (2002). "Changes in mechanosensitive channel gating following mechanical
stimulation in skeletal muscle myotubes from the mdx mouse." The Journal of physiology 539(Pt 2): 391-407.
3
http://www.ncbi.nlm.nih.gov/protein/NP_005316.1
4
Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M., and Kunkel, L.M. (1986). Isolation of
candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323:646-650.
http://www.dmd.nl/isoforms.html
5
"ProtParam for human titin". ExPASy Proteomics Server. Swiss Institute of Bioinformatics.
http://web.expasy.org/cgi-bin/protparam/protparam1?Q8WZ42@1-34350@
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--Figure 1. Schematic representation
of dystrophin gene taken from He
et al (He, Yi et al. 2013) (A),
protein isoforms (B), dystrophin
mutational spectrum (C). (A) The
dystrophin gene is depicted as a
2500 kb arrow pointing from the
centromere to the telomere,
promoters are shown as rightangled arrows coming off the
main arrow with a letter depicting
promoter name and dystrophin
protein (Dp) in kDa as a number.
B, brain promoter (Nudelet al.,
1989); M, muscle promoter
(Klamut et al., 1990); P, purkinje
promoter (Gorecki et al., 1992); R,
retina promoter (D'Souza et al.,
1995); B=K, brain and kidney
(Lidov et al., 1995); S, Schwann
cell (Byers et al., 1993); G,
general giving rise to both Dp71
(Bar et al., 1990) and Dp45
(Tinsley et al., 1993). (B) Key followed by schematic representations of the various translated
products from the dystrophin gene. Key: ABS, actin-binding sites 1±3, 4 and 5, WW, WW
domain; EF, EF hand calcium-binding domain; ZZ, ZZ zinc finger domain; DCC, predicted
dimeric coiled coil. Protein schematics are shown aligned under the key with different shaped
regions depicting the different domains. Alternatively spliced exons are shown in black and as a
square-bracketed 18 below the C terminus of full-length dystrophin, indicating the 18 alternative
splice variants in this region (see Fabbrizio et al., 1994, for review).

1.1.2. The Protein
Dystrophin is expressed in muscle, kidney, brain and other human tissues (Chelly,
Kaplan et al. 1988). In muscle, the dystrophin protein is a physical adapter between extracellular
matrix (ECM) and intracellular cytoskeleton (Figure 2). Based on stoichiometry, Ghate et al have
shown that one dystrophin binds directly to 24 actin monomers (Ghate, Baker et al. 2011).
Dystrophin binds to ECM indirectly through dystroglycans and sarcroglycans. Mutations on
3

dystroglycans and sarcroglycans both lead to distinct forms of muscular dystrophies (Medvedev,
Murro et al. 2011). Baron et al have shown that the sarcolemma of the dystrophin-deficient (mdx)
mouse muscles is four time less stiff than that of control mice (Baron, Hecht et al. 2011),
indicating a mechanical role for dystrophin.
The absence of dystrophin results in alteration in membrane structure, which is related to
the dystrophin-associated proteins. The dystrophin-associated protein complex is part of a riblike
lattice structure called the costamere.(Olamaei, Cheriet et al. 2010). These anchor the
cytoskeleton to the ECM (Rybakova, Patel et al. 2000), and distribute contractile forces
generated in the muscle fiber laterally through the sarcolemma to the basal lamina in ECM and
thereby maintain uniform sarcomere length along the fiber (Danowski, Imanaka-Yoshida et al.
1992). Absence of dystrophin protein leads to complete loss of the dystrophin-associated protein
complex and disruption of costamere lattice, resulting in excessive membrane fragility
(Rybakova, Patel et al. 2000). In addition to these mechanical functions, signaling functions of
dystrophin have been theorized as discussed in Chapter 4.

4

Figure 2. The dystrophin protein in muscle linking the internal cytoskeleton to the extracellular
matrix. From (Morelli, Runge et al. 2011)

1.1.3. The Disease Phenotype
DMD patients manifest skeletal muscle weakness and fat/fibrosis infiltration in their first
decade and succumb to respiratory or cardiac failure before the third decade (He, Yi et al. 2013).
DMD skeletal muscle biopsy characteristically reveals necrotic and degenerating muscle fibers,
surrounded by macrophages and CD4+ lymphocytes. Smaller immature centrally nucleated
fibers reflect ongoing muscle cell regeneration (Deconinck and Dan 2007). Raised levels of
muscle enzymes (CK) in DMD patients offer evidence of sarcolemma fragility that occurs after
exercise (Stepkowski 2003; O'Brien, Stinson et al. 2008). Subsequent skeletal muscle necrosis
and fibrosis result in loss of contractility, eventually in respiratory failure, and ultimately death
from muscle weakness. Monitoring of the disease progression with MRI (Magnetic Resonance
Imaging) can define regional heterogeneity among various muscle groups, and assess treatment
efficacy for limiting fatty infiltration and fibrosis (Kim, Laor et al. 2010; Kim, Laor et al. 2010).
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Histological analysis of DMD hearts demonstrates replacement of myocardium by connective
tissue or fat (Schmidt, Burmeister et al. 2003). Fibrosis and diastolic dysfunction precede overt
dilated cardiomyopathy (DCM), which is subsequently complicated by heart failure and
arrhythmia (Judge, Kass et al. 2011). In DMD patients, the basal posterior-lateral wall is mostly
affected by fibrosis, sparing the apex, RV, and atrium. However, even under these circumstances,
heart failure may be induced by stress testing in the face of normal cardiac function at rest
(Sethna, Rockoff et al. 1988; Schmidt, Burmeister et al. 2003).
Cardiac dysfunction accounts for 10~20% mortality in DMD, making it the second
leading cause of patient death after respiratory failure (Gulati, Saxena et al. 2005). Cardiac
dysfunction develops later than does respiratory dysfunction, but advances in respiratory support
and patient care have allowed patients to survive into their late 20s and 30s or ordler. (Ishikawa,
Bach et al. 1999; Ahuja, Kalra et al. 2000; Wagner, Lechtzin et al. 2007) Accordingly, cardiac
complications now are commanding closer scrutiny in the management of advanced disease in
DMD patients (Finsterer and Stollberger 2007; McNally 2008; Hermans, Pinto et al. 2010;
Romfh and McNally 2010).
The early manifestations and functional consequences of DMD cardiomyopathy have
been summarized recently by Judge et al in (Judge, Kass et al. 2011):
The cardiomyopathy that develops in DMD is characterized by normal or
thinned left ventricular (LV) wall thickness and progressive decline in
ejection fraction or fractional shortening. Variable degrees of LV dilation
occur. Abnormal LV relaxation 6 has also been identified as an early
manifestation in DMD.
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This abnormal relaxation presages the experimental results in section 2.5 showing that cardiac sheet function is
normal in systole but abnormal in diastole.
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Notably in DMD, cardiac diastolic dysfunction precedes systolic dysfunction, as
observed by Doppler ultrasound (Markham, Michelfelder et al. 2006) and tissue Doppler
ultrasound (Bahler, Mohyuddin et al. 2005). DMD cardiomyopathy also exhibits regional
abnormalities: MRI scar imaging detects early onset of fibrosis at the epicardium of the more
basal segments (Toyota, Fujimoto et al. 2002; Yilmaz, Gdynia et al. 2010). MRI tagging
methods have revealed abnormal strain at the base but not the apex in patients with normal
ventricular function (Ashford, Liu et al. 2005) as a manifestation of occult cardiac dysfunction.
Mertens et al. reported signiﬁcantly decreased early diastolic myocardial velocities in the
anterolateral and inferolateral left ventricular walls with normal global systolic function (Mertens,
Ganame et al. 2008). The previous work by Dr. Wickline’s group using MR tagging uncovered
occult abnormal wall strains occurring regionally at the base of heart in DMD patients (Ashford,
Liu et al. 2005) has been supported by subsequent reports by Li et al suggesting that cardiac
mechanical strain abnormalities are more prominent in the basal segments of hearts in mdx mice
(Li, Liu et al. 2009). These studies indicate that regional myocardial dysfunction precedes global
systolic dysfunction and validates the importance of advanced imaging techniques as tools for
early delineation of DMD cardiomyopathy.

The observed regional dependencies for DMD cardiac mechanical dysfunction remain to
be explained, as the mutation is present in all cardiomyocytes (Bulfield, Siller et al. 1984; van
Deutekom, Bremmer-Bout et al. 2001; Banks and Chamberlain 2008).
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1.1.4. Treatment Options
Unfortunately, there is no effective curative treatment, but palliative therapy has
advanced in clinical trials over the last 20 years. To date, the only active pharmacologic
interventions proven beneﬁcial for the altering the natural history of the underlying dystrophic
process have been the corticosteroids: prednisone and deﬂazacort (Rinaldi, Mayer et al. 2013).
Both medications have been shown in clinical trials to lead to modest improvements in muscle
strength and function, although the duration of these beneﬁts typically lasts less than 2 years and
the mechanism remains undefined (Araujo, Bonuccelli et al. 2013; Hollinger, Gardan-Salmon et
al. 2013). Importantly, azathioprine (an immunosuppressant) and prednisone both decrease DMD
muscle inﬂammatory inﬁltrates equally, but only prednisone improves strength (Griggs, Moxley
et al. 1991; Kissel, Lynn et al. 1993). Animal studies have shown that prednisone enhances
strength in dystrophin deficient transgenic mice that lack T-cells and B-cells, indicating
prednisone’s therapeutic effect does not operate through T-cell/B-cell immune suppressive
pathways (Golumbek, Keeling et al. 2007).
β-adrenergic receptor blockers, angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin II-type 1 receptor blockers (ARBs) are also used for treating DMD cardiomyopathy
(Duboc, Meune et al. 2007; Ogata, Ishikawa et al. 2009; Fayssoil, Nardi et al. 2010). Our group
has demonstrated a beneficial effect of ACEi on reducing fibrosis and calcium content in Syrian
hamster with cardiomyopathy, which harbors a related sarcoglycan deficiency. Although the
precise mechanism is unclear, a 10 year long clinical study showed that ACEi reduces DMD
mortality (Duboc, Meune et al. 2007). A large body of work on ACEi for scar tissue reduction
has demonstrated utility for inhibiting focal and global cardiac remodeling after myocardial
infarction by interrupting angiotensin signaling in the heart (Iwata, Cowling et al. 2011).
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1.1.5. The mdx mouse model
Animal models are valuable tools for studying the pathogenesis of disease and for preclinical trials. The mdx mouse is the most widely utilized animal model for DMD (Williams and
Allen 2007; Banks and Chamberlain 2008). It carries a point mutation leading to complete
absence of dystrophin in myocytes. Similar to the later onset of cardiomyopathy in human
patients, young mdx mice (< 3 months old) develop only a mild phenotype of cardiac disease and
exhibit normal resting [Ca2+]I (Williams and Allen 2007; Van Erp, Loch et al. 2010). However,
both dilated cardiomyopathy and elevated resting [Ca2+]i begin to be observed by about 10
months of age (Quinlan, Hahn et al. 2004; Williams and Allen 2007). Since mdx mice share the
same genetic defect as DMD patients, they represent a standard model for assessing cardiac
dysfunction and therapeutics.

1.1.6. Calcium Overload Hypothesis
With respect to pathophysiological features of dystrophin deficiency potentially
responsible for mechanical dysfunction, several recent studies in isolated cardiomyocytes of mdx
mouse have suggested that intracellular calcium ([Ca2+]i) mishandling is a key causative factor
(Williams and Allen 2007; Fanchaouy, Polakova et al. 2009; Allen, Gervasio et al. 2010). Data
acquired from mdx mice showed elevated resting [Ca2+]i in dystrophin-deficient cardiomyocyte
(Pressmar, Brinkmeier et al. 1994; Williams and Allen 2007). The calcium overload activates
calpains to promote proteolysis leading to cardiomyocyte degeneration (Spencer, Croall et al.
1995; Spencer and Tidball 1996; Gailly, De Backer et al. 2007). The calcium mishandling might
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also affect the cardiac contraction that is controlled by calcium induced calcium release
(Bellinger, Reiken et al. 2009).
Specifically, (Sapp, Bobet et al. 1996) reported that under 1 Hz pulse stimulation, peak
force and time-to-peak force were similar in both mdx and wildtype cardiac fibers, but halfrelaxation time was significantly prolonged in mdx, indicating normal contraction but abnormal
relaxation. However, (Alloatti, Gallo et al. 1995; Janssen, Hiranandani et al. 2005) both reported
depressed contractile force in mdx cardiac fiber, as compared to wildtype. This reported disparity
in normal versus abnormal contractile force might be a consequence of a higher stimulation
frequency used by Alloatti (4 Hz) and Janssen (2.8Hz). Nicolas et al reported abnormally
prolonged relaxation in mdx skeletal muscles, while the active contraction metrics were normal
(Nicolas-Metral, Raddatz et al. 2001), suggesting a decreased capacity for calcium removal in
mdx cells leading to alterations of muscle relaxation that accords with the observation that
diastolic dysfunction precedes systolic dysfunction in DMD patients and mdx mice (section
1.1.3).
Several mechanisms for elevated resting [Ca2+]i have been proposed, offering
opportunities for developing new therapies. One promising therapeutic approach is to inhibit the
calcium influx that occurs through SAC (stretch activated channels) or through transient
microruptures of the sarcolemma. It is well recognized that mdx cardiomyocytes are sensitive to
stretch induced injury that is correlated with increased resting [Ca2+]i (Lynch 2004; Yeung and
Allen 2004). Inhibition of SAC or the application of the membrane sealant poloxamer 188
reduces resting [Ca2+]i and prevents injury (Yasuda, Townsend et al. 2005; Whitehead, Streamer
et al. 2006; Ward, Williams et al. 2008). In vivo application of poloxamer 188 also protects mdx
mice from heart failure during dobutamine mediated cardiac challenge (Yasuda, Townsend et al.
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2005). Inhibiting the leakage of ryanodine receptor (RyR2), a calcium release channel located on
the sarcoplasmic reticulum, is another emerging therapeutic approach (Bellinger, Reiken et al.
2008; Shannon 2009). Notably, the RyR2 of mdx cardiomyocytes appears to be hypernitrosylated,
which prevents RyR2 from fully close at resting state (Bellinger, Reiken et al. 2009). The
resulting sarcoplasmic reticulum calcium leakage through RyR2 is indicated by the presence of
calcium sparks (Ward, Schneider et al. 2000). Several 1-4-benzothiazepine derivatives, such as
S107 and KD201, can stabilize RyR2 to reduce calcium leakage and improve cardiac function
(Wehrens, Lehnart et al. 2004; Lehnart, Terrenoire et al. 2006).
Besides pharmaceutical approaches, transgenic approaches provide potential remediation
of calcium mishandling. The root cause of DMD is the lack of dystrophin, making transgene
therapy for correction of the dystrophin gene preferable to altering calcium handling genes.
However, clinical studies suggest that immunity to transgenic micro-dystrophin in DMD patients
represents a significant challenge, because patients that are dystrophin-null recognize transgenic
micro-dystrophin as an exogenous antigen (Mendell, Campbell et al. 2010). Therefore,
transgenic strategies based on endogenous genes, such as sarco/endoplasmic reticulum Ca2+ATPase (SERCA), may offer an immune advantage as compared to dystrophin gene therapies.
Indeed, cardiac SERCA2a gene transfection has been shown to correct ECG abnormalities in
heart (Shin, Bostick et al. 2011); and skeletal SERCA1 gene transfection corrected skeletal
muscle calcium reuptake in dystrophic mice (Goonasekera, Lam et al. 2011).
The previously reported lack of efficacy of L-type calcium channel blockers against
DMD associated muscular dystrophy should not negate the potential value of calcium channel
targeted therapy (Phillips and Quinlivan 2008). L-type calcium channels regulate calcium inflow
upon depolarization and are closed in the resting state. Since calcium leakage through these
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channels has not been reported, L-type calcium channels’ effect on regulating resting [Ca2+]i
should not be expected to be significant.
In summary, calcium targeted therapy holds potential for treating DMD. Because calcium
influx cannot be measured in vivo in heart tissue, we propose that development of a surrogate
cardiac phenotype that reflected [Ca2+]i would be useful for evaluating the efficacy of treatment.
We have previously shown that left ventricular myocardial architecture changes dynamically in
cardiac cycle due to calcium regulated contraction-relaxation (Chen, Liu et al. 2005).

1.1.7. Hypothesis
How calcium mishandling influences cardiac mechanical dysfunction in whole heart
preparations has not been clarified, especially taking into account cellular and mechanical events
that are spatio-temporally distributed and regionally heterogeneous (DeAnda, Komeda et al.
1998; Balzer, Furber et al. 1999). Given the recognized abnormal and regionally heterogeneous
wall strains (Figure 3) and fibrosis (Ashford, Liu et al. 2005; Yilmaz, Gdynia et al. 2008; Yilmaz,
Gdynia et al. 2010) in DMD hearts of both human patients and mdx mice, we hypothesize that
the sheet functional consequences of dystrophin deficiency plays out regionally in DMD hearts
over time despite the ubiquitous lack of dystrophin protein in all cardiomyocytes. We
hypothesize that elevated resting [Ca2+]i directly affects myofiber and sheet kinetics in mdx
mouse hearts which can be quantified by diffusion tensor MRI (DTI, Chapter 2).
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Figure 3. Cardiac MRI detected
abnormal strain at base but not
apex of DMD patient hearts,
indicating base exhibits more
myocardial dysfunction than
apex. Figure from (Ashford,
Liu et al. 2005)

The heart comprises a syncytium of cardiomyocytes that are organized in unique 3D fibersheet architecture that is critical for optimizing a coordinated sequence of excitation, contraction,
and relaxation (Streeter and Hanna 1973; Costa, Takayama et al. 1999). Many reports have
shown that sheet function produces a sliding motion that is accompanied by dynamic
reorientation in systole, contributing to approximately 50% of focal wall thickening (LeGrice,
Smaill et al. 1995; LeGrice, Takayama et al. 1995; Costa, Takayama et al. 1999; Dou, Tseng et
al. 2003; Chen, Liu et al. 2005). Significant sheet-fiber deformation was also found in early
diastole (Ashikaga, Criscione et al. 2004). Because one role of dystrophin is to anchor
cardiomyocytes to the extracellular matrix to coordinate contraction-relaxation coupling, we
propose that dystrophin deficiency could adversely affect sheet function. Given that ventricular
wall strain vary regionally from base to apex, and in light of the expected vulnerability of
dystrophin deficient cardiomyocytes to stretch-induced membrane injury, we sought to examine
the role of sheet function in the regional mechanical defects reported in the DMD
cardiomyopathy (Ashford, Liu et al. 2005; Li, Liu et al. 2009). We investigated the heart sheet
structure defect in regions of heart with ultra high-field MRI, because MRI is non-destructive
and provides functional assessment according to the methodology described in Chapter 2.
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Examination of this regional structural functionality may add to the fundamental understanding
of the nature of the heart dysfunction in DMD and lead to improved early monitoring of
interventions designed to salvage cardiac structure and function.
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Chapter 2: MRI for Cardiac Sheet Function

2.1. Cardiac muscle structure
The normal architecture of the heart muscle remains elusive despite recent advance in high
resolution images offered by MRI and photoacoustic imaging (Gilbert, Benson et al. 2007).
Several models have been proposed to explain cardiac structure without reaching a consensus.
Therefore, accurate knowledge about the architecture of heart muscles is critical in
understanding normal heart and cardiomyopathy. A comprehensive understanding of myocardial
architecture would help us to (1.) explain cardiac electric and mechanical mechanics; (2.)
simulate cardiac physiology; (3.) design intervention/monitoring strategy; and (4) understand
structure-function relationship of the heart. In the future, we could compare myocardial
architecture among fish, amphibian, reptile, bird, and mammal, to understand the evolution of the
heart, in which lies the natural history of how the heart adapts the gravity and land environments
with high pressurizing ability. A comprehensive review of cardiac architecture during 17th
century and year 2002 can be found in a MIT doctorate dissertation (Dou 2002). Below is my
review of recent update.

2.1.1. Fiber
Myocardial fibers are cardiac muscle cells, which include sarcolemma and bundles of
parallel or sometimes branching myofibrils. Cell and fiber are terms that may be used
interchangeably (Pollack 1990). The 3D myocardial architecture is critical for optimizing a
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coordinated sequence of excitation, contraction, and relaxation (Streeter and Hanna 1973; Costa,
Takayama et al. 1999). The earliest study of fiber helical path was a reprint in Latin by Stensen
in 1664. An English review can be found in (Dou 2002).
Based on laborious histology work, Streeter reported a smooth transition of fiber helix
angle (α, angle between fibers and local circumferential axis) in the transmural direction (Figure
4) Streeter proposed a wicker basket model to explain how α might reflect the ventricular volume
(Figure 4 B). However, the basket model represents the LV incorrectly, because recent studies
have found that helix angle decreases during longitudinal extension (i.e., diastole) (Chen, Liu et
al. 2005). In contrast, the wicker basket model predicts increased α during longitudinal extension
(Figure 4 B). Nevertheless, a smooth transmural transition of α is observed in many mammalian
species (Scollan, Holmes et al. 1998; Tseng, Wedeen et al. 2003; Chen, Liu et al. 2005; Helm,
Beg et al. 2005). Chen 2005 found that Δα is decreased by ~7 degree in diastole compared to
systole. This small change was not detected by Streeter with his histology method (Streeter and
Hanna 1973), probably due to the unavoidable dehydration/deformation artifacts of histology
specimen preparation.
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Figure 4. A. Cartoon of LV fiber orientation from (Streeter and Hanna 1973). Green: epicardial
fiber, left handed helix. Blue: midcardial fiber, circumferential. Red: endocardial fiber, right
handed helix. B. Streeter’s proposed wicker basket model of helix angle change between diastole
and systole.

2.1.2. Sheet
Robert Grant conceived and illustrated how fibers might aggregate into a laminar sheet
structure (Grant 1965) (Figure 5). But the laminar sheet structure was not actually visualized
until 1995 by LeGrice using the histology method (LeGrice, Smaill et al. 1995). The discovery
of the myocardial sheet exemplified how an obvious structure eluded scientists for a long time.
All of the popular experimental mammalian hearts exhibit laminar structures, similar to layers of
muscle found in a fish fillet (Figure 6). Myocardial sheet is about four layers of fibers
aggregating into a laminar structure (simply called a “sheet” in this thesis). Figure 7 shows the
sheet architecture in a fresh, unfixed and unstained mouse left ventricle (Zhang, Cheng et al.
2012). Figure 7 is acquired with advanced photoacoustic microscopy (PAM) system. The
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significances of the PAM image of myocardial sheet are (1) it is the highest resolution of unfixed
sheet to the best of my knowledge; (2) the heart is unfixed, meaning there’s minimal dehydration
artifacts compared to formalin fixed hearts; (3.) it requires no staining nor contrast agent, saving
time and artifacts of doing so; (4) it is a three dimensional imaging modality, suitable for
investigating the 3D structure like the heart muscle. For technical details, please refer to (Zhang,
Cheng et al. 2012).

Figure 5. Robert Grant proposed that “planes” can be
formed by fibers. “Schema of fiber to fiber
relationship which appears to obtain typically in the
left ventricle. While fibers are parallel, by their
branchings they form ‘planes’ which appear to rotate.”
(Grant 1965)

Figure 6. Cooked fish fillet shows sheet structure of
skeletal muscle of fish, indicating muscle fibers
aggregate into secondary structure in a form of sheets.
Cooking helps the separation of sheets, indicating the
connective tissues between sheets are more vulnerable
to thermal denaturation. The major difference between
fish sheet and mammal myocardial sheet is in the fish,
fiber is parallel to sheet normal direction. In contrast, in
myocardial sheet, fiber is perpendicular to the sheet
normal direction.
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Figure 7. Photoacoustic microscopic (PAM) image of a unfixed, unstained, and un-dehydrated
myocardium, showing sheet structure of a mouse left ventricle. (a), PAM image of the left
ventricle free wall (FW) marked in (c) acquired at 532-nm wavelength. (b), Close-up PAM
image. The boundaries of the branching sheets are apparent. Red dashed line: long axis. Yellow
dashed-dot line: sheet boundary. (c), Photograph of the heart specimen. LV, left ventricle; RV,
right ventricle. (Zhang, Cheng et al. 2012).

Here is a chronicle summary of important discovery on sheet. After LeGrice visualized
the sheets with histology (LeGrice, Takayama et al. 1995), Costa and Chen inferred that sheet
shearing contributes dominantly to heart wall thickening using radiocinegraphy and DTI,
respectively (Costa, Takayama et al. 1999; Chen, Liu et al. 2005). Using diffusion tensor MRI
on alive human subjects, Dou reported that sheets change orientation in cardiac cycle (Dou,
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Tseng et al. 2003). Specifically, sheets align closer to short axis in systole than diastole. Using
confocal histology, Pope reported that sheet presents dominantly at mid- and endocardium but
not at epicardium (Pope, Sands et al. 2008). Using 9.4T MRI with 3 day long scan time, Gilbert
confirmed Pope’s finding whith the field of view of a whole heart, revealing more mysterious
helical nature of sheets in high resolution (25µm) (Gilbert, Benoist et al. 2012). Readers are
directed to view the spplemental movie in Gilbert’s paper for the 3D whole heart sheet structure.

2.1.3. Nomenclature of the heart segments
Figure 8 illustrates the terminology used to describe the various regions of the heart. This
terminology follows AHA consensus (Cerqueira, Weissman et al. 2002).

Figure 8. Left ventricle (LV) is rounded in shape in short axis view. Right ventricle (RV) has a
semilunar shape. Aorta and vena cava are closer to the heart base than the apex. Apex is pointing
to the left in normal human chest. Heart base is physically closer to the head and has larger
diameter than apex.
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2.2. Diffusion Tensor MRI
2.2.1. Background
MRI modulates magnetic field to affect nuclear spins to form images (Appendix). Under
magnetic gradient, the diffusion of molecules dephases the nuclear spins and thus decreases MR
signal. DTI (Diffusion Tensor MRI) quantifies the ADC (apparent diffusion coefficient) from the
signal decay. Specifically, the DTI signal predominantly comes from nuclear spins of water
protons. In spin echo imaging, the signal intensity is governed by eq1.
𝑆 = 𝑃𝐷(1 − 𝑒 −𝑇𝑅/𝑇1 ) 𝑒 −𝑇𝐸/𝑇2 𝑒 −𝑏𝐷

(eq1)

S is signal intensity, PD is proton density, T1 and T2 are relaxation (decay) times of protons
within the samples under given B0. D is the ADC, which represents the observed Brownian
motion of water molecules in tissue. TR and TE are repetition time and echo time. b is the
diffusion-weighing factor with units of s/mm2. From eq1, one can see higher b value decreases S
(Basser 1995).
TR, TE and b can be adjusted on the scanner. Longer TR and shorter TE generate better
signal to contrast ratio (SNR) but require longer scan time and faster responding electronics,
which are both more expensive. Tradeoff was made between SNR and scan time. We want D for
the diffusion information in it, but it is impossible to calculate the D with just one S in eq1.
Therefore Stejskal and Tanner devised the two-S method to calculate the D (Stejskal 1965). See
equations below:
𝑇𝑅

𝑇𝐸

𝑆1 = 𝑃𝐷 (1 − 𝑒 − 𝑇1 ) 𝑒 − 𝑇2 𝑒 −𝑏1 𝐷 = 𝑆0 𝑒 −𝑏1 𝐷
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…….measurement 1

𝑇𝑅

𝑇𝐸

𝑆2 = 𝑃𝐷 (1 − 𝑒 − 𝑇1 ) 𝑒 − 𝑇2 𝑒 −𝑏1 𝐷 = 𝑆0 𝑒 −𝑏2 𝐷
𝑆2
𝑆1

…….measurement 2

= 𝑒 −( 𝑏2 − 𝑏1 ) 𝐷

(eq2)

Rearranging eq2, we obtain:
𝑆

𝐷 = − ln (𝑆2 ) /( 𝑏2 − 𝑏1 )

(eq3)

1

That is, we can derive a scalar D by attenuating the signal with two different b values. For
example, I have used b1= 0, and b2=800 (s mm-1) in my work.

2.2.2. Restricted Diffusion
Brownian motion of water molecule in an isotropic diffusion environment is
characterized by a single parameter, the diﬀusion coeﬃcient, D. For example, in threedimensional space, random walkers spread with time t according to a Gaussian distribution
would have a mean square displacement, E(x2) = 6Dt. That is, in isotropic diffusion environment,
D is the same in all direction. However, complexity in the microscopic structure of myocardium
restricts water molecular motion anisotropically and results in non-Gaussian diffusion and hence
different values of D in different directions. Therefore, instead of a single scalar D, multiple Ds
are required to describe the diffusion anisotropy.
To detect anisotropic diffusion, one could repeat Stejskal’s two measurements method
(eq3) in 6 non-collinear directions to fill in the following matrix D:
𝐷𝑥𝑥
𝑫 = 𝐷𝑦𝑥
𝐷𝑧𝑥

𝐷𝑥𝑦
𝐷𝑦𝑦
𝐷𝑧𝑦

𝐷𝑥𝑧
𝐷𝑦𝑧
𝐷𝑧𝑧

(eq4)
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The D in eq4 is a 3 x 3 matrix, which is also a rank 2 tensor. For example, Dxx is the ADC in
x direction. Dxy is ADC in xy direction, which is in the same direction of the vector
(x,y,z)=(1,1,0). From the diffusion tensor, D, we can assess magnitude of ADC in different
directions. Specifically, the ADC is found to be the greatest in fiber direction and smaller in
perpendicular directions. Therefore, the tensor not only provides the orientation information (e.g,
which direction has the largest ADC) but also relative ratios of ADCs in different directions (i.e.,
anisotropy of the diffusion environment, Chapter 3). The fact that water diffusion is restricted by
the underlying tissue microstructure provides a unique method of assessing myocardium
architecture (Safford, Bassingthwaighte et al. 1978; Garrido, Wedeen et al. 1994; Ennis and
Kindlmann 2006).
In summary, DTI is an established method for 3D reconstruction of myocardial
microarchitecture that can depict structural changes across the heart cycle in the intact heart
(Chen, Liu et al. 2005; Sosnovik, Wang et al. 2009). The value of DTI is it is non-invasive, nondestructive, 3-dimensional and rapid, compared to traditional histology (Mori and Zhang 2006;
Roberts and Schwartz 2007).

2.1. Method: DTI for mdx mice cardiac structure
In the heart, the primary eigenvector is considered to be aligned with the local orientation of
cardiac myofibers, and thus defines the fiber angle (α) (Hsu, Muzikant et al. 1998; Scollan,
Holmes et al. 1998; Holmes, Scollan et al. 2000; Geerts, Bovendeerd et al. 2002). The secondary
eigenvector is aligned parallel to sheet surfaces (Tseng, Wedeen et al. 2003) and thus defines the
sheet angle (β, Figure 9 A). This definition system is based on the fact that eigenvalues of a
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diffusion tensor are also the apparent diffusion coefficients describing microscopic diffusion
movements, which are the largest in the fiber direction and second largest in the sheet direction
(Scollan, Holmes et al. 1998; Chen, Suzuki et al. 2005).

Figure 9. Representative DTI and histology images of sheet architecture in WT mouse hearts. A,
A local cylindrical coordinate system was used to describe LV myocardial structures. The
primary eigenvector (EV1) of the diffusion tensor is characterized by helix angle (α), which is
the angle between the circumferential axis and the projection of the first eigenvector onto the
circumferential-longitudinal plane; the α shown in A is set as negative. The secondary
eigenvector (EV2) is characterized by sheet angle (β), which is the angle between the secondary
eigenvector and the radial axis; the β shown in A, toward base and toward endocardium, is set as
negative. B & C, short-axis views of DTI determined sheet angle () in a basal slice of WT heart
that was sequentially arrested in diastole (B) and systole (C). The posterior-lateral wall of LV
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manifested two populations of , exhibiting positive (red) and negative (blue) values. D,
Histology of sheet organization in a WT heart. Images were acquired from the basal-lateral wall,
which is highlighted on the H&E stained image (insert). Two populations of  were
observed.(LV, left ventricle; RV, right ventricle; PA, papillary muscle; P, Posterior; L, Left; R,
Right; A, Anterior).

Experimental Methods
2.1.1. Langendorff perfusion for DTI
Animals
Adult male mdx (C57BL/10ScSn-Dmdmdx/J, N=14) and age matched male wild type
(WT: C57BL/10SnJ, N=10 and C57BL/6, N=3) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA) and the National Institute on Aging (NIA, MD, USA)(18)
and housed under a AAALAC-approved facility to 16-month of age. All mice were housed in the
same animal facility and cared for under approval by Washington University’s animal study
committee. All mice were separated into two groups for DTI and optical mapping studies
described below.

Isolated Heart Preparation for DTI
Ten mdx mice and ten WT mice were used for both diastolic and systolic DTI
measurement (Figure 10). Mice were heparinized (1000 U/kg) and anesthetized with isoflurane.
Hearts were excised and cannulated for retrograde perfusion using a procedure modified from
(Chen, Liu et al. 2005). Briefly, hearts were first perfused with Krebs buffer at 60 mmHg
constant pressure for approximately 5 min to wash out the residual blood. Five mdx hearts and
five WT hearts were perfusion-arrested in diastole (perfusion pressure = 60 mmHg) with regular
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St. Thomas’ cardioplegic solution containing normal [Ca2+] of 1.2 mmol/L (denoted as mdx-NC
and WT-NC, respectively) under room temperature.

DTI of diastolic arrested hearts was

performed for 1.5 hours. After that, hearts were reperfused with 37 ͦC Krebs buffer to resume
beating. Upon stabilization of contraction (~6 min, up to 300 beats per min), 2.5 mmol/L Ba2+
was then introduced to induce systolic cardiac contracture while Ca2+ was lowered to 0.078
mmol/L (Munch, Comer et al. 1980; Toyota, Fujimoto et al. 2002; Chen, Liu et al. 2005). To
evaluate the effect of [Ca2+] on diastolic cardiomyocyte architecture in mdx mice, another five
mdx hearts and five WT hearts were perfusion-arrested in diastole with a modified cardioplegic
solution containing low [Ca2+] of 0.078 mmol/L (denoted as mdx-LC and WT-LC, respectively).
The 0.078 mmol/L [Ca2+] was chosen over the calcium-free condition to minimize the risk of
complete depletion of intracellular calcium, which can cause calcium overload upon reperfusion
with solutions containing normal [Ca2+], thereby exerting unfavorable effects on certain ion
channels (Munch, Comer et al. 1980; Robinson and Harwood 1991).
The systolic arrest of mdx-NC, WT-NC, mdx-LC, and WT-LC (defined below) are all
achieved with the same modified Tyrode solution containing 2.5 mmol/L Ba2+ and 0.078
mmol/L Ca2+ (Chen, Suzuki et al. 2005). All solutions were equilibrated with 95% O2 plus 5%
CO2 (PH 7.4) and contained adenosine (45µmol/L) to maximally dilate the coronary vessels
(Judd, Rottman et al. 1992).

Bovine serum albumin (BSA; 61 µmol/L) was added to the

perfusate to minimize interstitial edema (Dunphy, Richter et al. 1999; Watts and Maiorano 1999).
DTI of systolic contracture hearts were conducted for ~1.5 hours. Upon the completion of MRI,
all hearts were perfused with 10% formalin for histological study.
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Figure 10. Flow chart for DTI acquisitions for diastolic and systolic arrested hearts. Left, ten
mice perfused with normal calcium (NC) concentration for diastolic arrest then high barium for
systolic arrest. Right, ten mice perfused with low calcium concentration (LC) for diastolic arrest
then high barium for systolic arrest. See text for details.
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2.1.2. Perfusion compatible MR Coil
A dedicated MRI-compatible retrograde mouse heart perfusion system was made. This
system provides a quantitative and non-destructive assessment of diastolic and systolic
myocardial architecture from the same heart. The system includes: (1) a custom-built 15 mmdiameter solenoid coil, which provides high SNR: 65 for non-diffusion weighted images and 40
for diffusion weighted images (See Figure 11 for the coil design.); (2) a Langendorff constantpressure perfusion apparatus. The constant perfusion pressure is controlled by a reservoir with
constant height. Perfusate efflux was removed by vacuum suction. The heart was contained in a
plastic tube made by syringe, which is omitted in Figure 11 for simplicity but is important to
prevent contact between perfusate and the copper coil. A variable capacitor was soldered at the
center of the gap of the single turn copper coil for resonance frequency tuning. The distance, h,
between the cable loop and the copper coil determines the coefficient of coupling, k, which
determines the mutual inductance, L.
𝐋 = k√𝐿1 𝐿2 , k is between 0 (when h is large) and 1 (when d is small)

(eq5)

The Figure 11 B is an equivalent circuit of my coil. The resonance frequency, 𝒇, of the
circuit can be determined by series RLC resonator. Practically, L and C were adjusted to
resonate at 499.70 MHz for the 11.7 tesla ultra-high field MR scanner used in this study.
𝑓=

1

(eq6)

√𝐿𝐶
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Figure 11. A. Cartoon of single turn
solenoid coil and perfused mouse heart
setup. A plastic tube containing the heart
and preventing perfusate from contacting
the copper coil is omitted for visual
simplicity. Distance between the cable
loop and the copper coil is denoted by h.
B. Equivalent circuit. R is the resistance
of loading (perfusate and heart) and
copper. L1 is the inductance of the cable
loop. L2 is the inductance of the copper
coil. C is variable capacitor.

2.1.3. Imaging parameters
All MRI experiments were performed on a Varian 11.7 tesla small animal MR scanner
(Varian Associates; Palo Alto, CA). Long-axis scout images were acquired as previously
described (Chen, Liu et al. 2005). A multislice spin-echo sequence with diffusion-sensitizing
gradients were used to acquire short-axis, diffusion weighted images. Diffusion-sensitizing
gradients were applied in six noncolinear directions. Imaging parameters were as follows: echo
time, 46 ms; time interval between diffusion-sensitizing gradients, 30 ms; b-value, 0 and 800
s/mm2; in-plane resolution, 125  125 µm2, repetition time, 3 s; and image-acquisition time, 1 h.
For diastolic arrested hearts, eight contiguous slices (thickness = 0.7 mm) extending from the
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base to apex were acquired. For systolic contracture hearts, eight contiguous slices were acquired
with slice thickness adjusted to 0.55–0.65 mm based on the fraction of longitudinal shortening.
Attention was paid to keep the slice selection and the heart orientation the same between diastole
and systole imaging.

2.1.4. Post processing, sheet angle calculation (β)
All MR images were processed using custom-developed software written in Matlab (The
MathWorks Inc., M.A., USA) as described previously (Chen, Liu et al. 2005). Specifically, fiber
helix angle (α) and sheet angle (β) were calculated based on a right-handed helix, the fiber helix
angle (α) was calculated as the angle between the circumferential cardiac axis and the projection
of the first eigenvector of the diffusion tensor onto the circumferential-longitudinal plane
(Scollan, Holmes et al. 1998). Sheet angle (β) was determined as the angle between the
secondary eigenvector and the radial axis. Sheet inclination toward the base from endocardium to
epicardium was set as positive (Figure 9 D) (Scollan, Holmes et al. 1998; Tseng, Wedeen et al.
2003). Because regional wall thickening is accompanied by a reduced magnitude of the sheet
angle, |β|, therefore |β| was used to analyze sheet function (LeGrice, Takayama et al. 1995; Chen,
Liu et al. 2005). LV wall thickness was calculated as the mean distance between epicardial and
endocardial borders. The transmural difference of α, deﬁned as the difference in endocardial and
epicardial helix angles, i.e., Δα = αendocardium-αepicardium, was used to quantify transmural changes
of ﬁber orientation.
2.1.1. Statistical methods
Statistical differences were assessed with the analysis of variance (ANOVA) or the
multivariate analysis of variance (MANOVA) as appropriate. Bonferroni correction was applied
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to post-hoc comparisons. A value of p < 0.05 was considered significant. Data were expressed as
mean  standard error of the mean (S.E.). All statistics were conducted with the IBM SPSS
Statistics program.

2.1.2. Histology
After DTI acquisition, five mdx and five wildtype hearts were rapidly fixed in 10% formalin.
Fixed hearts were sliced into four blocks with 2 mm thickness from base to apex. Each slice was
embedded in parafﬁn and sectioned at 4 μm thickness. The tissue sections were stained with
picrosirius red for the identiﬁcation of fibrosis (Van Erp, Irwin et al. 2006). The extent of
myocardial fibrosis was quantified from digitized histological images using a thresholding
algorithm implemented in Matlab. Regions that demonstrate stronger red-to-green ratio in
picrosirius red staining were considered to represent interstitial fibrosis. The percentage of tissue
fibrosis was calculated as the ratio of pixels representing fibrotic tissue vs. pixels of the entire
short-axis slice, and the average value in two adjacent slices was used in analysis.

2.2. Results: Sheet function in 16-month old mdx mouse hearts
2.2.1. Morphological observation of β with histology and PAM
DTI, histology, and PAM all show a similar transmural morphological character of sheet,
that is, a sharp change of β at midmyocardium of basal posterior mid-wall (Figure 12).
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Figure 12. A & B, representative short-axis view of DTI determined sheet angle ( ) in a basal
slice of the same WT heart that was sequentially arrested in diastole (A) and systole (B). The
posterior-lateral wall of LV possessed two populations of , exhibiting positive (red) and
negative (blue) values. The transmural portion of positive  is increased in systole (compare the
portions of red-colored pixels under the dashed lines in A & B). The dotted line in B indicates a
3 population  transition that appears only in systole. C, Photoacoustic microscopy of long-axis
view of a freshly half-split WT mouse heart confirmed two populations of  in LV wall. The
insert showed H&E stained long-axis WT mouse heart slice with the corresponding region of
photoacoustic image squared. LV: left ventricle. RV: right ventricle. PA: papillary muscle.

2.2.2. 16 month old mdx hearts manifest reversible regional diastolic sheet
dysfunction
DTI defined two populations of β with opposite signs in the LV wall of WT and mdx
mice, as confirmed by several previous reports (LeGrice, Smaill et al. 1995; Tseng, Wedeen et al.
2003; Chen, Liu et al. 2005; Helm, Beg et al. 2005; Gilbert, Benson et al. 2007; Pope, Sands et
al. 2008). Under conditions of barium-induced systolic arrest, | | value is decreased in systole
(Figure 9 B&C, Figure 13 A&B), agreeing with in vivo and ex vivo observations (LeGrice,
Smaill et al. 1995; LeGrice, Takayama et al. 1995; Costa, Takayama et al. 1999; Chen, Liu et al.
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2005). At each short-axis imaging slice, the slice-averaged systolic | | was comparable among all
groups of hearts (Figure 13 B, p = N.S.). However, the diastolic | | of mdx hearts (mdx-NC) was
~10° lower than that of WT hearts (WT-NC) at the base when perfused with regular cardioplegic
solution (p < 0.05, Figure 13 A). The | | at the apex of mdx-NC hearts appeared normal (p = N.S.
compared to WT-NC at each corresponding short-axis imaging slice), demonstrating that
diastolic sheet dysfunction in mdx hearts occurred focally at the base. By reducing the [Ca2+] of
the cardioplegic solution to 7% of its regular concentration, a complete and rapid restoration of
diastolic | β | in mdx hearts (mdx-LC) to normal values was observed. No effect of calcium
manipulation on WT cardiac sheet function was observed (WT-LC, p = N.S. compared to WTNC at each corresponding short axis imaging slice), indicating that the diastolic sheet
dysfunction in mdx hearts was substantially calcium dependent. These data suggest that even at
this advanced age, a principle mechanical abnormality in mdx mice likely is associated with
regionally-dependent incomplete sarcomere relaxation.
At the base, further regional analysis indicated that the maximal decrease of diastolic |β|
in mdx-NC hearts occurred in the endocardium. Compared to WT-NC, mdx-NC exhibited 13°
lower |β| (75° ± 2° vs. 62° ± 3°) in the endocardium (inner 1/3 wall-depth in transmural
direction); 10° lower |β| (74°± 1° vs. 64° ± 2°) in the midcardium (middle 1/3 wall-depth in
transmural direction); and 8° lower |β| (68° ± 2° vs. 60° ± 2°) in the epicardium (outter 1/3 walldepth in transmural direction) (Figure 13 C). Moreover, in the posterior-lateral wall, the diastolic
|β| was 51° ± 6° in mdx-NC (Figure 13 F). This value was approximately 20° lower than that of
mdx-LC (70°± 4°), as well as that of WT-NC (72° ± 4°) or WT-LC (72° ± 6°) groups ( p < 0.05
for all comparisons. See post hoc multiple comparison in Table 2 in page 107). Together these

33

findings indicate a clear regional and transmural dependence of incomplete relaxation, despite
the ubiquitous dystrophin mutation.

34

35

Figure 13. DTI-determined diastolic and systolic |β| in short-axis slices. A, mdx hearts exhibited
abnormally lower diastolic |β| that was recovered to normal value after reducing [Ca2+] in the
perfusate. For hearts perfusion-arrested in diastole with normal calcium solution, mdx hearts
(mdx-NC) exhibited lower |β| than did WT (WT-NC) hearts with the maximal ~10 degree
difference occurred at the basal region. In contrast, mdx hearts perfused with the low calcium
solution (mdx-LC) exhibited normal diastolic |β|. Varying [Ca2+] had no effect on diastolic |β| in
WT hearts (WT-LC). B, systolic |β| exhibited no difference among four groups of hearts. C,
diastolic |β| in the epicardium, midcardium, and endocardium at the base of WT and mdx hearts.
In all regions, diastolic |β| of mdx-LC hearts were comparable to that of WT-LC and WT-NC
hearts, but all are higher than that of mdx-NC hearts. The largest difference in diastolic |β|
between mdx-LC and mdx-NC was observed in the endocardium. D & E, representative DTIdetermined diastolic |β| maps on short-axis slices at the base of mdx-NC and mdx-LC hearts. The
lower |β| in mdx-NC heart, indicated by fewer regions with red color, was visually appreciable. F,
in the posterior-lateral region (the areas enclosed by dashed line in D & E), the diastolic |β| of
mdx-NC hearts was approximated 20 degree lower than that of mdx-LC hearts and of all WT
hearts. Data represent mean ± SEM. N = 5 for each group. *, p < 0.05; †, p <0.005 for the
indicated short axis location.

2.2.3. 16 month old mdx and WT hearts exhibit similar fiber organization and
function
Wall thickness and through-wall differences of myofiber helix angle (Δα) were similar
between mdx and WT mice (Figure 14), suggesting that the major mechanical abnormality was
confined to sheets rather than fibers. The normal wall thickness agrees with former publications
(Li, Liu et al. 2009; Stuckey, Carr et al. 2012)
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Figure 14. Averaged wall thicknesses in each short axis slice are similar in all four groups, in
both diastole (A.) and in systole (B.) Averaged through-wall myofiber helix angle differences
(Δα) in each short axis slice are similar in all four groups, in diastole (C.) and in systole (D.).
Overall, Δα is increased in systole, agreeing with a prior publication (Chen, Liu et al. 2005). No
significance was detected in all comparison in each panel.

2.2.4. 3 month old mdx mice exhibit smaller sheet dysfunction, still reversible by
low calcium perfusion
The max difference in |β| between mdx-NC and mdx-LC is 6.1˚˚ (p < 0.66, Table 3 in
page 110) and 9.3˚2.26˚ (p < 0.005, Table 2 in 107), both at base in 3- and 16-month old mice
respectively (Figure 15), indicating that this [Ca2+]-dependent sheet dysfunction is also loci
dependent.
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Figure 15. A. |β| of 3 month old mdx and WT mice under normal calcium (NC) and low calcium
(LC) perfusion. B. |β| of 16 month old mdx and WT mice under NC and LC perfusion. Data
represent mean ± SEM. N = 5 for each group. *, p < 0.05; †, p < 0.005 for the indicated short
axis location.
2.3. Discussion of |β|
This study shows for the first time that mdx hearts exhibit an abnormal myocardial sheet
angle magnitude, |β|, in diastole but not in systole. Agreeably, Goldberg reported that DMD
patients have abnormally slower wall thinning but normal wall thickening in echocardiography
(Goldberg, Feldman et al. 1980) (Figure 16), indicating that dystrophin affects normal diastolic
rather than systolic function. Furthermore, regional and intramural gradients of diastolic
dysfunction (Figure 13 A & C) are evident, primarily in the more basal segments where
abnormal calcium handling also occurs (Chapter 4).
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Figure 16. Using
echocardiography, Goldberg
has shown that DMD patient
heart has significantly slower
wall thinning but normal wall
thickening, indicating that the
absence of dystrophin affects
diastolic function more than
systolic function, agreeing with
the DTI measured sheet angle
data in Chapter 2. Figure from
(Goldberg, Feldman et al. 1980).

These co-localized abnormalities in calcium handling and diastolic calcium-dependent sheet
dysfunction strongly suggest that features other than the simple absence of dystrophin are critical
to the evolution of heart failure in DMD. Indeed, it is well recognized that the mechanical defect
in the dystrophin encoding gene does not independently elicit DMD cardiac dysfunctions such as
reduced circumferential wall strain (Ashford, Liu et al. 2005), which emerge in a regionally
heterogeneous fashion over time, and not at all loci where dystrophin is missing. This locidependency agrees with my findings.
Given that systolic |β| < diastolic |β| (Figure 13 A & B), the observed lower diastolic |β| in
mdx heart may reflect that cardiomyocytes are not fully relaxed in diastole. We also confirmed
that this regional diastolic sheet dysfunction in mdx hearts is a likely consequence of cytosolic
calcium mishandling, because the regional diastolic sheet dysfunction is quickly reversible upon
perfusion with a lower level of calcium (Figure 13 A, mdx-NC vs mdx-LC).
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Chapter 3: Anisotropy information in DTI
3.1. Introduction
In Chapter 2, I have used orientation information (β) derived from DTI to detect the basal
myocardial function abnormality. In this Chapter, I sought for the first time to further explore the
shape information with fractional anisotropy (FA) and mode of anisotropy (mode) to elucidate
regional abnormal myocardial fiber/sheet shape in mdx mice hearts. Please refer to Chapter 2 for
DTI background and methods. Refer to Advanced Engineering Mathematics by Erwin Kreysiz
(9th ed) for tensor matrix properties.
Each diffusion tensor can be decomposed into three eigenvectors and three corresponding
eigenvalues. Eigenvectors carry orientation information, while eigenvalues provide anisotropic
information for the micro-diffusion environment in the voxel (Bahn 1999). A tensor invariant is
a scalar value calculated from eigenvalues. For examples, trace and norm are wildely used tensor
invariants in DTI:

𝑡𝑟𝑎𝑐𝑒 = 𝜆1 + 𝜆2 + 𝜆3 = 3 × 𝐴𝐷𝐶,

𝑤ℎ𝑒𝑟𝑒 𝜆1~3 𝑎𝑟𝑒 𝑒𝑖𝑔𝑒𝑛𝑣𝑎𝑙𝑢𝑒𝑠
………..eq10

𝑛𝑜𝑟𝑚 = √𝜆1 2 + 𝜆2 2 + 𝜆3 2
………..eq11

In an eigenvalue space of a 3-D Cartesians coordinate system, norm is the distance between
the origin and the point, (λ1, λ2, λ3). Trace is the sum of the coordinates. The trace is three times
of the quantity of the apparent diffusion coefficient (ADC), which is an effective indicator of
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stroke-sites in brain (van Gelderen, de Vleeschouwer et al. 1994; Latt, Nilsson et al. 2009). The
norm is a measure of total magnitude of diffusion (Grant 1965). Trace and norm are both in the
units of mm2/sec, the same as the unit of eigenvalues.
For example, fractional anisotropy (FA) and mode are two independent scalar values
calculated from eigenvalues (Figure 17). FA has been widely used in many DTI measurements
(Pierpaoli and Basser 1996), especially in the brain (Papanikolaou, Karampekios et al. 2006).
Recently, FA has been applied to delineate the contraction-induced assumption of more isotropy
for tissue architecture in skeletal muscle (Galban, Maderwald et al. 2004; Deux, Malzy et al.
2008). Mode was proposed in 2006 as an FA-independent metric for anisotropy (Ennis and
Kindlmann 2006). Mode has been used to detect microstructural anatomy of epidermoid cysts
and nerve fibers (Jolapara, Kesavadas et al. 2009; Douaud, Jbabdi et al. 2011). However,
dynamic changes in myocardial architecture for genetically abnormal dystrophic hearts have not
been investigated with the use of FA or mode. Although FA is more widely used in DTI, we
propose to include also mode to describe the anisotropy in myocardium, because “No single
scalar parameter can be constructed which reﬂects all of the information about anisotropy which
is contained in the eigenvalues” (Bahn 1999). The 3D information acquired in perfused viable
mdx hearts should allow delineation of both the locus (regional and intramural) and the cycle
dependence (diastole vs. systole) of the principle cardiac defects in dystrophin-deficiency and
whether these defects might be reversible (i.e. functional) consequences of calcium mishandling
(please refer to Chapter 4) or be nonreversible
consequences of fibrosis (i.e., remodeling).

Figure 17. Demonstration of anisotropic space spanned
by FA and Mode. From (Ennis, 2006)
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3.2. Method: DTI Data Analysis for FA and mode
Please refer to Chapter 2 for isolated Heart Preparation for DTI and MRI procedure. The
dataset is the same as acquired in Chapter 2. However, new signal processing method was used
to extract information from the dataset. All MR images were processed using custom-developed
software written in Matlab. FA and mode are both calculated from eigenvalues and eigenvectors
of tensors according to the standard formulas below (Ennis and Kindlmann 2006).

𝐹𝐴 = √

1 √(𝜆1 − 𝜆𝑚𝑒𝑎𝑛 )2 + (𝜆2 − 𝜆𝑚𝑒𝑎𝑛 )2 + (𝜆1 − 𝜆𝑚𝑒𝑎𝑛 )2
2
√𝜆1 2 + 𝜆2 2 + 𝜆3 2

= √

3 √(𝜆1 − 𝜆2 )2 + (𝜆2 − 𝜆3 )2 + (𝜆1 − 𝜆3 )2
2
√𝜆1 2 + 𝜆2 2 + 𝜆3 2

, 𝑤ℎ𝑒𝑟𝑒 𝜆1~3 𝑎𝑟𝑒 𝑒𝑖𝑔𝑒𝑛𝑣𝑎𝑙𝑢𝑒𝑠 𝑎𝑛𝑑 𝜆𝑚𝑒𝑎𝑛 𝑖𝑠 𝑡ℎ𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝜆1~3
………..eq12

𝑚𝑜𝑑𝑒 = 3 √6 det (

𝐴𝑎𝑛𝑖𝑠𝑜
√(𝑒𝑣1 + 𝑒𝑣2 + 𝑒𝑣3 )
) , 𝑤ℎ𝑒𝑟𝑒 𝐴𝑎𝑛𝑖𝑠𝑜 = 𝐴 −
× 𝐼3
|𝐴𝑎𝑛𝑖𝑠𝑜 |
3
…………eq13

3.3. Result
3.3.1. mdx and WT hearts exhibit lower FA & higher mode
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In all hearts, systolic FA was ~40% lower than diastolic FA (p < 0.05 for all comparisons,
Figure 18), indicating that a more isotropic diffusion environment was elicited by cardiac
contraction (Galban, Maderwald et al. 2004; Deux, Malzy et al. 2008), as expected from fibers
shortening in the long-axis and expanding in the short axis (i.e., becoming rounder, or less
oblong). Generally, systolic FA is lower (i.e., spherical instead of a ellipsoidal shape) and mode
is higher (i.e., oblong instead of a discoid shape, Fig63) than those of diastole (Fig64). In diastole,
mdx-NC hearts exhibited abnormally low FA and high mode compared to WT, indicating a
regional unrelaxed myocardial fiber/sheet architecture. After perfusing the mdx heart with low
[Ca2+] (mdx-LC in Fig64) cardioplegic solution, recovery of diastolic FA and mode to normal
values were observed.
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Figure 18. DTI-determined FA and mode in diastole and systole of WT and mdx mouse heart. N
= 5 for each group. *, p < 0.05. NC, normal calcium. LC, low calcium concentration perfusion.
See Methods in Chapter 2.

3.4. Discussion – abstract shape information
The low diastolic FA of mdx hearts, indicating more isotropic fiber/sheets organization
(Galban, Maderwald et al. 2004; Deux, Malzy et al. 2008), also demonstrates this diastolic
mechanical defect of mdx hearts. Systolic FA of mdx is lower than that of WT, indicating while
the mechanical sheet orientation is not affected by the absence of dystrophin in systole, the
microstructural environment of muscular architecture is affected. This requires further
investigation.
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This study shows for the first time that myocardium microstructure of mdx mice exhibits
abnormal anisotropy that is calcium dependent, loci-dependent,7 and rapidly reversible. Given
that barium-induced cardiac contraction leads to lower FA and higher mode, the observed lower
diastolic FA and higher diastolic mode in mdx hearts all reflect that mdx cardiomyocytes are not
fully relaxed in diastole.
FA and mode describe the anisotropy of water diffusion in the microscopic environment that
could represent several factors, including cell shape/size, extra/intracellular volume ratio,
myofiber dispersion, and myocardial sheet extension, all of which broadly impact
electromechanical cardiac function. The observation that changing cytosolic [Ca2+] regulates the
FA and mode in mdx hearts suggests that restoration of cell environment by allowing complete
relaxation in diastole can be achieved rapidly by transient adjustments in sarcoplasmic calcium
levels. Accordingly, diastolic dysfunction in mdx mice may be reversible in part with measures
aimed at restoring normal calcium handling, and is not a permanent pathophysiological feature of
the disease. Thus, FA and mode are quantitative tissue based metrics to assess microarchitectural
alterations in cardiomyopathy.
4.

7

Loci-dependent: base is abnormal while apex is normal.
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Chapter 4: Optical mapping for calcium transients in ex vivo viable
mdx hearts
4.1. Acknowledgements to the contribution of Dr. Efimov’s lab
After I have found the calcium-dependent regional sheet dysfunction described in last
Chapter, Samuel Wickline and me proposed a collaboration to Igor Efimov’s lab to test the
hypothesis of regional abnormal calcium handling in a whole perfused mouse heart. I thank Di
Lang, Chaoyi Kang, and Igor Efimov for their generous help on optical mapping for studying the
calcium transients of 16 month old (old) and 3 month old (young) mdx mice. Di found that the
basal calcium transients are abnormally prolonged only when the heart is stretched in old but not
young mdx mice, for the first time. Combining Di’s optical mapping findings with my DTI
findings, we were able to infer that mdx cardiomyopathy is calcium- and loci- dependent (Cheng,
Lang et al. 2012).

4.2.

Why use optical mapping for calcium?

Ca2+ released by sarcoplasmic reticulum (SR) in cardiac muscle triggers conformation
change in troponin, allowing the binding between actin and myosin and the following sliding
action, and results in macroscopic contraction of cardiac muscle. The Ca2+ is released from the
openings of SR Ca2+ release channel (ryanodine receptor, RyR). The voltage-gated sarcolemmal
L-type Ca2+ channels (dihydropyridine receptors, DHPRs) locally increase [Ca2+]i and thereby
activate the RyRs by Ca2+-induced Ca2+ release (CICR). After contraction, sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) uptake the cytosol Ca2+ into SR, allowing relaxation (Cheng,
Lederer et al. 1996). This CICR and Ca2+ recycling triggers every heart cycle. How
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cardiomyocytes handle calcium is critical to both normal and pathological hearts. Chapter 2
suggests mdx mice exhibit calcium-dependent sheet dysfunction at base, leading us to
hypothesize that the base handles calcium differently than the apex. We employed optical
mapping to investigate calcium handling of mdx mouse hearts for the first time.
Optical mapping of calcium transients in ex vivo, viable, and intact heart (simply “optical
mapping” hereafter) uses a camera to capture the time-varying fluorescence signals of calciumsensitive dyes. Efimov’s group pioneered the technique two decades ago (Efimov, Huang et al.
1994). The optical mapping technique is a powerful tool to investigate cardiac calcium transients
in human, dog and mouse (Fedorov, Chang et al. 2010; Lang, Glukhov et al. 2011; Cheng, Lang
et al. 2012). However, one needs to either open the chest or prepare an ex vivo Langendorff
perfused heart to provide access the heart to optical cameras.
For interested readers, the best publication introducing the setup of optical mapping is on
The Journal of Visualized Experiments (Lang, Sulkin et al. 2011), which is also from Efimov’s
lab. It utilizes online video streaming to explain the complex setup efficiently and clearly.
http://www.jove.com/video/3275/optical-mapping-action-potentials-calcium-transients-mouse

4.3.

Method

4.3.1.

Isolated heart preparation and calcium dye loading

Seven Langendorff-perfused hearts (Lang, Glukhov et al. 2011) from 16 month old mice were
separated into two groups (mdx, N=4; and WT(C57BL/6), N=3). In brief, after anesthesia and
heart excision, a short section of aorta was attached to a 21-gauge cannula. After cannulation,
hearts were superfused and retrogradely perfused with oxygenated (95% O2, 5% CO2) constant-
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temperature (37±1oC), modified Tyrode solution (in mmol/L: NaCl 128.2, KCl 4.7, NaH2PO4
1.19, MgCl2 1.05, CaCl2 1.3, NaHCO3 20.0, and glucose 11.1 (pH=7.3)) that was passed through
a 5 μm filter (Millipore, Billerica, USA). Perfusion was performed using a peristaltic pump (PeriStar, WPI, Sarasota, USA) under a constant aortic pressure of 60 – 80 mm Hg.
The isolated heart was pinned at the edge of ventricular apex to the Sylgard bottom of the
chamber to prevent stream-induced movement. A small silicon drain tube was inserted into the
left ventricle through the pulmonary vein, left atria, and tricuspid valve to prevent solution
congestion and subsequent ischemia. A piece of small black tape was used to cover the atria to
avoid fluorescence scattering from the atria. The excitation-contraction uncoupler Blebbistatin8
(10 µM, Tocris Bioscience, USA) was used to prevent motion artifact on the action potential
duration estimation. The heart was then stained with a calcium indicator (Rhod-2 AM, Invitrogen,
Carlsbad, CA, 30μL of 1 mg/mL dimethyl sulfoxide, 1:1 mixed with Fluronic F127, Invitrogen,
Carlsbad, CA in Tyrode’s solution), for 5-7 minutes.

4.3.2.

Optical imaging system

The excitation light was generated by a halogen lamp (Newport Oriel Instruments,
Stratford, CT; SciMedia, Costa Mesa, CA) and passed through a heat filter, shutter, and
excitation band-pass filter (520 ± 45 nm). A flexible light guide directed the band-pass filtered
light onto the preparation. The optical mapping apparatus comprised an MiCAM Ultima-L
CMOS camera (SciMedia, Costa Mesa, CA) with high spatial (100x100 pixels, 230±20 μm per
pixel) and temporal (1,000-3,000 frames/sec) resolution. A band-pass filter (59015 nm,
Thorlabs, Newton, NJ) was fixed in front of the calcium-imaging camera.

8

Blebbistatin will stop the muscle contraction, allowing motion free calcium transients recording.
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4.3.3. Optical mapping protocols
After isolation and cannulation, motion suppression, and dye staining, prepared hearts
were equilibrated for 5-10 min before imaging. The optical mapping signals were recorded
sequentially under unloaded and stretched conditions. The unloaded condition was achieved by a
pressure releasing silicon tube inserted into the LV chamber of the Langendorff heart preparation
mentioned above. The stretched condition was achieved by inflating the LV chamber with
Tyrode’s solution to 80 mmHg pressure through the silicon tube inserted into the left ventricle.
The perfusion pressure was increased from 60 to 100 mmHg to maintain the direction of the
retrograde perfusion and the viability of the perfused heart. A steady-state restitution (S1S1)(Lang, Glukhov et al. 2011) pacing protocol was applied under both conditions.

4.3.4. Optical mapping data processing
A custom-designed Matlab program was used to analyze the optical signals, which were
filtered with a low-pass Butterworth filter at 256 Hz. Regional calcium dynamics were quantified
in WT and mdx mouse ventricles (base vs. apex) under both unloaded and stretched conditions.
Hand-drawn regions of interest were used to define basal (upper 1/3 area of left ventricle) vs.
apical regions (lower 1/3 area of left ventricle). The calcium decay signal is not monoexponential
and only the latter half of the decay signal could be fitted exponentially to derive the decay
constant. Thus, both T50 and decay constant (Figure 19 A) are commonly used to characterize
calcium relaxation kinetics (Giordano, He et al. 1997; Vassalle and Lin 2004; Zhu, Altschafl et
al. 2005; Mukherjee, Apple et al. 2006; Taylor, Al-Saadi et al. 2006; Williams and Allen 2007;
Sahoo and Kim do 2008; Sahoo, Kim et al. 2009; Chase and Orchard 2011; Mellor, Wendt et al.
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2012). Specifically, Ca relaxation time from the calcium transient peak value to 50% relaxation
(T50) was calculated to define the early calcium reuptake phase; and Ca decay constant was
calculated using an exponential curve fitting program from the 50% calcium peak value to ful
relaxation. Taken together, the T50 and the decay constant characterize the whole process of Ca
reuptake-dependent relaxation.

4.4.

Optical Mapping Results

4.4.1. Optical imaging reveals longer calcium decay time (T50) in 16 month old
mdx mice
Under unloaded conditions, T50 was comparable between mdx and WT hearts. However,
ventricular stretch elicited an approximately 25% increase in T50 (from 40  2 ms to 51  3 ms,
p < 0.05, Figure 19) and approximately 50% increase of decay constant (from 25  1 ms to 37 
1 ms, p < 0.05) at the base of mdx hearts, confirming abnormal calcium uptake in this region.
Ventricular stretch, however, did not affect the T50 nor decay constant at the apex of mdx hearts,
nor in the entire left ventricle of WT hearts, indicating a heterogeneous regional dependency on
the development of abnormal calcium handling in mdx.
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Figure 19. Calcium relaxation for mdx and WT. A, representative calcium transients at the base
of a WT (blue line) and a mdx (red line) hearts. Signals were averaged from adjacent 25 CCD
elements. Definitions of T50 and  are illustrated. B & C, representative T50 and decay constant
maps in mdx and a WT hearts under unloaded versus loaded (stretched) condition. D & E, under
unloaded conditions, both T50 and decay constant were comparable between mdx and WT hearts.
Ventricular stretch caused regional increases of T50 and decay constant at the base of mdx hearts.
However, WT hearts exhibit similar T50 and decay constant. *, p < 0.05; **, p < 0.01.

4.4.2. 3 month old mdx mice exhibit normal calcium transients

51

Surprisingly, despite the fact that mdx mice lack dystrophin since embryo, the prolonged
calcium transient abnormality did not exist in young mice (3 month old) whether stretched or not,
while abnormal calcium transient exist at the base of old mdx mice (16 month old), only when
stretched. Representative figures are shown in Figure 20.

Figure 20. Calcium transient duration at 80% relaxation is only abnormal (red) in 16 month old
mdx when stretched; but is normal (blue) when young or unstretched. T50 and decay constant
exhibit the same pattern (not shown).

4.5.

Discussion of regional abnormality at base

The prior recognition of stretch induced calcium mishandling in isolated mdx
cardiomyocytes informs the present work (Williams and Allen 2007; Fanchaouy, Polakova et al.
2009). Specifically, mechanical stretch increases opening chance of stretch-activated channels
(SAC) (Williams and Allen 2007) and induces transient membrane microruptures in mdx
cardiomyocytes (Townsend, Blankinship et al. 2007; Townsend, Yasuda et al. 2007). The
resultant leakage of extracellular calcium into the cytosol then compromises calcium clearance
during relaxation and renders mdx cardiomyocytes vulnerable to stretch induced injury (Sapp,
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Bobet et al. 1996). In this study of intact perfused hearts, we employed a stretch protocol to
mimic cardiomyocyte activity under moderate strain regimes by inflating LV pressure to 80
mmHg, which is similar to that used for investigating fibrillation by several groups (Nazir and
Lab 1996; Bode, Katchman et al. 2000; Zarse, Stellbrink et al. 2001; Eijsbouts, Majidi et al.
2003; Huang, Tai et al. 2003). Under the stretched condition, mdx hearts exhibited regional
deficiency in calcium uptake, as evidenced by the prolonged T50 and decay time constant, at the
base where the sheet functional defect was observed. Thus, our results illustrate a regional
correspondence between abnormal diastolic sheet mechanics and disturbed calcium kinetics.
Because sheet function is a key determinant of ventricular wall strain (Costa, Takayama et al. 1999; Usyk,
Mazhari et al. 2000), and calcium mishandling in mdx cardiomyocytes is associated with cellular injury
(Lynch 2004; Williams and Allen 2007; Prosser, Ward et al. 2011), the observed stretch-induced regional
calcium mishandling in mdx hearts may be responsible in part for the local progression of diastolic sheet
dysfunction.

4.6.

Discussion of the perfusion condition in DTI and optic mapping

Results in Chapter 2 and 3 agree that abnormalities exist at the base of mdx hearts. However,
Chapter 4 suggests the calcium transient abnormalities only when the left ventricle (LV) is
stretched by 80 mmHg pressure. Why do I see abnormalities at base in Chapter 2 without
stretching? Here is a possible explanation: In the DTI study, the LV was not vented, while in the
optical mapping study, the LV was vented with a tube inserted in the LV through left atrium. I
did not use the venting tube in DTI study, in order to avoid susceptibility artifacts and sliding
motion-artifact of the tube. A venting tube in LV creates two surfaces of water/non-water
materials and usually brings microbubbles into the LV. The surfaces and microbubbles both
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generate unwanted susceptibility artifacts of MRI (Sakurai, Fujita et al. 1992). Furthermore, the
tube tends to slide by few millimeter during the 1.5 hr long DTI study and generate motion
artifacts. However, in optical mapping, all the signals were collected from the surface of a heart.
Therefore, a tube in the LV does not affect optical imaging but does prevent the congestion of
the perfusate and metabolism acidification in the LV, making a venting tube desirable for optical
mapping study. In DTI, the metabolism acidification is less worrisome because the heart was
arrested in diastole with the cardioplegic solution under 18 Celsius temperature which minimize
the metabolism activity. In conclusion, in DTI study, all the hearts are not vented, therefore, the
LV might be stretched by the perfusion pressure delivered through aorta valve incompetence or
the Thebesian veins, during the 30~45 min long imaging setup time. In the future, a thin pressure
transducer can be used to measure the pressure in the unvented LV for prolonged DTI
acquisition to clarify this issue.
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5.

Chapter 5: Autophagy and Beneficial Effects of Rapamycin-nanoparticle

5.1. Acknowledgements
Experiment were designed by Bibee Kristine, Jon Marsh, Samuel Wickline and me. Richard
Killing and I performed strength measurements. Sharron Yang and I performed autophagy
nanoparticle treatments. Huiying Zhang and I performed histology of myocardium.
Echocardiography ejection fraction were performed and processed by Dr. Jon Marsh. Western
blots were performed by Dr. Kristine Bibee and Dr. James Ching.

5.2. Abstract
Current supportive therapy for DMD patients with corticosteroids results in a modest
increase in strength as a consequence of a general reduction in inflammation, albeit with
potential untoward long-term side effects and ultimate failure of the agent to maintain strength.
Here, we demonstrate that rescuing defective autophagy in mdx mice, a model of DMD, with the
use of rapamycin-loaded nanoparticles (RNP) induces a reproducible increase in both skeletal
muscle strength and cardiac ejection fraction that is not achievable with conventional oral
rapamycin delivery. Rapamycin induces autophagy, or “self-eating”, which is a cellular process
responsible for recycling metabolites and eliminating toxic byproducts. The resulted increase in
physical performance occurs in both young and adult mice, and surprisingly even in aged wildtype mice. RNP treatment of old mdx mice increases autophagic activity with rapid beneficial
consequences for improved LV function after only eight doses.
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5.3. Introduction
As discussed earlier, DMD now is treated symptomatically with corticosteroids, resulting in a
modest increase in strength albeit with expected and unavoidable side effects (Balaban,
Matthews et al. 2005; Markham, Spicer et al. 2005; Moxley, Ashwal et al. 2005; Biggar, Harris
et al. 2006). However, the cardiac phenotype has proven difficult to modify, and pursuit of
combination therapies that might be steroid sparing remains an active area of research (van
Deutekom, Janson et al. 2007; Kinali, Arechavala-Gomeza et al. 2009; Cirak, ArechavalaGomeza et al. 2011; Goemans, Tulinius et al. 2011).
New pharmaceutical strategies other than steroid are desirable. A recent promising treatment
target is the autophagy pathway, which is a cellular process responsible for recycling reusable
products of metabolism and/or efficient elimination of toxic byproducts (Kundu and Thompson
2008). Indeed, rapamycin, a known inducer of autophagy, was reported by Eghtesad et al.
(Eghtesad, Jhunjhunwala et al. 2011) in 6-week-old mdx mice to improve diaphragm muscle
histopathology. Protein restriction has been shown to activate autophagy in 16-week-old mdx
leading to enhanced grip strength (De Palma, Morisi et al. 2012). Recent work by Pauly et al.
has demonstrated that autophagy induction in the diaphragm of 6-week-old mdx animals by daily
intraperitoneal injections of an AMP-activated protein kinase agonist also promotes clearance of
defective mitochondria and improves diaphragm strength (Pauly, Daussin et al. 2012). However,
the potential benefits of enhancing autophagy in multiple muscle groups with the use of
clinically practicable therapeutic agents that might elicit rapid and repeatable responses in both
global physical performance and cardiac functionality in vivo over a broad range of ages (e.g.,
≥16 months) have not been examined.
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Rapamycin, an immune-suppressing macrolide typically used to prevent organ transplant
rejection and as an anti-inflammatory agent to prevent angioplasty restenosis (Vilquin, Asselin et
al. 1995; Thomson, Turnquist et al. 2009; Adelman), is known to induce autophagy, thereby
inciting a cell survival program that enables useful recycling of amino acids via non-specific
degradation of long-lived proteins and dysfunctional organelles (Shigemitsu, Tsujishita et al.
1999). By binding to the mammalian target of rapamycin complex 1 (mTORC1), rapamycin
blocks proliferative signaling (Wullschleger, Loewith et al. 2006). Paradoxically, blocking
mTORC1 with rapamycin might be expected to exert deleterious effects on protein synthesis,
muscle fiber regeneration, and cell growth in mdx mice, all of which might be expected to
maintain strength. However, if autophagy is fundamentally defective in DMD/mdx and can be
shown to reverse weakness and cardiac dysfunction, and if a method for effective delivery of
clinically approved doses of rapamycin to muscle tissues that might enhance autophagy and
improve endurance can be designed, then a compelling mechanistic link between disturbed
autophagy and progressive deterioration of global physical strength and contractile performance
in vivo would be suggested.
Nanoparticle therapeutics for treating cancer and other pathologies are now undergoing
clinical trials in multiple drug combinations (Etheridge, Campbell et al. 2013), but heretofore
have not been evaluated in neuromuscular diseases. The potential advantage conferred by such
agents is their high local accumulation at sites of disease in concert with the use of lower serum
levels of free drug that would limit unwanted off targeted side effects, as has been shown for
Doxil™ and Abraxane™ in cancer for example.

Accordingly, we compared both an oral

preparation of rapamycin and an intravenous nanoparticle-based formulation of rapamycin (RNP)
for ability to improve a clinically significant global performance factor related to endurance and
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grip strength, with the use of validated methods that are translationally relevant and highly
correlated with mortality in the mdx model (Keeling, Golumbek et al. 2007). Furthermore, we
measured autophagic responses to rapamycin nanoparticles in skeletal muscle tissues for
correlation with grip strength metrics (designed and performed by Jon Marsh and Kristine Bibee).
Finally, we delineated the effects of these agents on cardiac function in aged mdx and wild-type
mice.

5.4. Methods
5.4.1. Reagents
All chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA) unless
otherwise specified.
5.4.2. Nanoparticle formulation
The perfluorocarbon nanoparticle emulsions without or with rapamycin (at a
concentration of 0.275 mol%) were prepared as previously described (Cyrus, Zhang et al. 2008).
In general the sizes of the PFC NP range between ~160-240 nm (Wickline, Neubauer et al. 2006;
Wickline, Mason et al. 2010). As an example, batch MS1-92b exhibited a diameter of 184.7 nm,
polydispersity 0.120, and zeta potential -15.31 mV. We note from prior experience that drug
loading has little effect on the size but may affect zeta potential depending on the exact
composition and charge of the loaded moiety (Soman, Lanza et al. 2008; Soman, Baldwin et al.
2009). An additional, dual-fluorophore emulsion was formulated to verify delivery of both
nanoparticles and rapamycin to skeletal muscle. The emulsion lipid moiety incorporated
rhodamine B (Avanti Polar Lipids, Alabaster, AL, USA), and the rapamycin was conjugated
with a near-infrared (IR) fluorescent dye (Cy7.5, Lumiprobe Corporation, Hallandale Beach, FL)
before formulation into the nanoparticles. Perfluorocarbon nanoparticles are exceedingly stable
in blood as they were originally developed as a blood substitute (Flaim 1994). The stability of
rapamycin incorporated into nanoparticles has been reported previously (Cyrus, Zhang et al.
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2008). Drug release kinetics against an infinite sink of releasing medium in vitro verified
retention of 97% of nanoparticle rapamycin over three days.
5.4.3. Animal studies
Strength studies:

Male mdx mice (strain C57BL/10ScSn-Dmdmdx/J) and age-matched

controls (strain C57BL/10SnJ) were purchased from The Jackson Laboratory (Bar Harbor, ME,
USA). All mice were housed in the same animal facility and cared for under approval by
Washington University’s animal study committee. Starting at age 14 weeks, mice were injected
twice weekly for four weeks with plain nanoparticles (n=18 for mdx, n=4 for control) or
nanoparticles loaded with rapamycin (n=16 for mdx, n=5 for wild-type). Dosage was 1 mL
emulsion/kg body mass, injected via lateral tail vein resulting in approximately 0.002 mg
rapamycin per animal per treatment. An additional set of mdx (n=8) mice was housed in an
AAALAC-approved facility until they were 17 months of age, at which point they received 4
weeks of RNP treatment as described above.
Separate groups were utilized for oral rapamycin therapy. For these animals, rapamycin was
solubilized in grain alcohol and was delivered in a mixture of dextrose and water twice weekly
for four weeks via micropipette gavage, typically 40–50 µL per mouse. There were three
treatment groups: mdx mice given rapamycin (n=6); control mice given rapamycin (n=6); and
mdx mice given placebo (n=6).
Treatment effectiveness was determined by measuring forelimb grip strength within one
week before beginning each treatment regimen, and subsequently within one week after
treatment completion. Strength testing was performed in blinded fashion by an experienced
technician as previously described by our group (Keeling, Golumbek et al. 2007) and by others
who have used this standardized test of physical fitness and endurance. Strength testing was
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performed using a grip meter attached to a force transducer (E-DF 002 Digital Force Gauge,
Chatillon Force Measurement Systems, Largo, FL, USA).

The tests relied on the animal’s

instinct to grab hold as it was pulled backward. Each mouse was grasped by the tail and
encouraged to grab a trapeze bar attached to the force transducer using its forelimbs. The mouse
was then pulled away and the peak force was recorded on a digital display. This procedure was
repeated five times in a row for each animal. The three highest readings were averaged and
normalized by the animal’s weight to give the strength score.
Rapamycin nanoparticle drug holiday studies: To determine if the effects of RNP on grip
strength were reproducible in individual animals, a cohort (n=7 for mdx/no drug, n=8 for
mdx/rapamycin, n=4 for wild-type/no drug, and n=5 for wild-type/rapamycin) of the originally
treated 14-week-old mice was maintained off drug therapy over the span of 18-34 weeks of age
to allow washout of the RNP effect. The same one month RNP treatment and grip strength
testing regimen was then repeated for 1 month starting at age 34 wks.
Cardiac studies: A cohort of 17-month old mdx mice received either RNP (n=9) i.v. via eight
tail vein injections (1.5 mL/kg/dose), 2x/week over four weeks to deliver the same cumulative
amount of rapamycin as for the other studies above or no treatment (n=7). Wild-type mice of the
same age were used as controls (n=6 for RNP, n=8 for no treatment). The mice were lightly
anesthetized for cardiac ultrasonography with isoflurane and placed supine for examination with
a 16 MHz array (Spark, Ardent Sound, Inc., Mesa, AZ, USA). Prior to imaging, the thorax of
each animal was shaved and depilated. Animal body temperature was maintained with a heated
water blanket and thermistor-controlled heating lamp. Heated ultrasound coupling gel was
liberally applied to the shaved area. Waveforms were sampled at the system's clock frequency
(66.67 MHz) using a 12-bit digitizer (GaGe Compuscope 12400, DynamicSignals LLC,
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Lockport, IL, USA). Two hundred frames of cardiac data were acquired for each view at a frame
rate of 152 Hz, with each frame consisting of 128 A-lines (2048 sampled points/line). Each loop
thus consisted of between 8 and 12 heart cycles. Radiofrequency (RF) data were converted to
scaled image data using custom plugins written for the open-source image processing software
ImageJ (Rasband, W.S., U. S. National Institutes of Health, Bethesda, MD, USA,
http://imagej.nih.gov/ij/, 1997-2013). Backscattered ultrasound energy was mapped to grayscale
by taking the log of the sum of the squares of the digitized voltage values in a center-weighted
moving window. The resulting image loops were scaled to a resolution of 0.05 mm/pixel. Left
ventricular ejection fraction (LVEF) was computed using ImageJ by manually tracing the
ventricular endocardium border at systole and diastole in the short-axis (SAX) view for each beat
and by recording the area region of interest (ROI). Ventricular length was computed from the
long-axis (LAX) view by determining the length of a line manually drawn from the apex
endocardium to the aortic valve plane. Left ventricular volume at systole (or diastole) was
estimated by computing the volume of an ellipsoid having a circular cross-section equal to the
mean systolic (or diastolic) ROI area and length equal to the mean systolic (or diastolic)
measured ventricular length. LVEF was then computed as the ratio of the difference in volume
of this ellipsoid between diastole and systole, and the diastolic volume.

5.4.4. Histology
Fibrosis imaging was performed in the diaphragm by analyzing trichrome stained (Masson),
formalin-fixed sections (8-µm thickness) with a stain kit (HT-15-1KT, Sigma-Aldrich) and in the
heart with picrosirius red stains per standard protocol (Dolber and Spach 1987). Color light
microscope images of collagen were acquired from five randomly selected fields for each
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diaphragm section at 200X with an Olympus BX61 microscope and F-View camera (Olympus
America Inc., 3500 Corporate Parkway, Center Valley, PA, USA). Similar assessments were
performed for basal heart sections from 5 treated and 5 untreated mdx. Custom software (written
as a plugin for ImageJ) was used to quantify the area of each image associated with collagenlabeled pixels relative to the area of each image associated with tissue of any type.
For fluorescence histologic imaging, 14-week old mdx mice were given intravenous
injections (1 mL/kg) of dual-labeled fluorescent nanoparticles and sacrificed 4 hours postinjection following systemic saline perfusion to wash out any residual circulating nanoparticles.
Nanoparticle and/or rapamycin tissue distribution was demonstrated in the biceps, diaphragm,
gluteus, and myocardium of mice injected with fluorophore-loaded emulsions in excised and
frozen (OCT medium: Tissue-Tek, Sakura Finetek, Torrance, CA, USA) or paraffin-embedded
tissues. Sectioning (8-µm) was performed on 10 consecutive slides from each tissue sample (a
total of 60 slides were prepared), and random sections were chosen by a blinded observer for
fluorescence microscopy. Adjacent slides were saved for H&E. Multiple images were acquired
from each section with an Olympus BX51 fluorescence microscope image system, using an
Infinity3 camera (Lumenera Corporation, Ottawa, Ontario, Canada) for optical image recording
and digitization, and F-View II B&W CCD camera for fluorescent images.

Tissue nanoparticle biodistribution
19

F perfluorocarbon-core nanoparticles were administered to 14 mdx mice (18 weeks old)

by tail vein injection; and tissue and organ harvesting conducted at either 2, 12, or 24 hours.
Tissues harvested for measurement of nanoparticle concentrations were acquired after in situ
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perfusion fixation of the mouse that was initiated by cardiac puncture and flow-through of buffer
solution until venous effluent was clear (~10 min). This washout procedure ensured that blood
contamination was not a factor in the estimation of tissue nanoparticle content. We also note that
the tissue distributions and clearances for similar particles are not affected by drug loading and
have been reported before for mice and rabbits (Hu 2007; Soman, Lanza et al. 2008; Soman,
Baldwin et al. 2009). The specimens were blotted dry, weighed, fixed in formalin, and then
subjected to fluorine spectroscopy with the use of an 11.7T Varian MRI/MRS scanner and a
custom-built single-turn solenoid coil.

19

F spectra signal from each specimen and from a

standard of perfluoro-15-crown-5 ether were obtained via non-localized 90-FID spectroscopy
(2.5-s pulse repetition time TR, and 128, 256, or 512 signal averages NT). The unique and
quantitative fluorine signature was expressed as total tissue fluorine content per gram. This
methodology fortunately avoids the necessity for extraction of the target compound
(perfluorocarbon in this case) with its attendant inefficiencies, since the total amount of

19

F

signal in the entire unprocessed tissue can be registered nondestructively. Because there is a
direct and linear relationship between the

19

F signal and the nanoparticle concentration, the

analytical method yields essentially the nanoparticle concentration per unit tissue mass
(Morawski, Winter et al. 2004).

Creatine Kinase
Blood was obtained by left ventricular cardiocentesis, and serum extracted by
centrifugation. Serum creatine kinase (CK) levels were measured spectrophotometrically with a
Vitros DT60 dry reagent chemistry analyzer (OrthoClinical Diagnostics, Raritan, NJ, USA).
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Autophagy and autophagic flux measurements
Muscle tissues were extracted from the mdx mice and homogenized in 0.5 mL of RIPA
buffer with 1-mM PMSF, Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA),
and Phosphatase Inhibitor Cocktail (Roche) using a glass grinding tube. The tissue homogenates
were centrifuged at 10,000xg for 10 min at 4°C and the supernatant was stored at -80°C.
Proteins in tissue homogenates were resolved on a NuPAGE Novex 4-12% Bis-Tris Gel
(Invitrogen, Carlsbad, CA, USA), transferred to 0.2 µM nitrocellulose, blocked in 5.0%
milk/TBS-T and incubated with the following primary antibodies: rabbit anti-pS6 (1:1000, Cell
Signaling 4857, Boston, MA, USA), rabbit anti-S6 (1:1000, Cell Signaling 2217), rabbit antiLC3B (1:2000, Sigma-Aldrich), rabbit anti-Beclin1 (1:1000, Cell Signaling), goat anti-actin
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Corresponding secondary antibodies
were used at 1:5000. Protein bands were visualized using either ECL Western Blotting Substrate
(Pierce 32106, Rockford, IL, USA) or Super Signal West Femto Maximum Sensitivity Substrate
(Pierce 34095). Western blot image was used to calculate relative protein expression using
densitometry with ImageJ. Values were normalized to myosin loading control and reported as
fold change compared to the control, non-treated sample.
To illustrate how this approach might apply to actual primary human cells and be
potentially generalizable, tumor cells (HIM3 line from the Washington University HAMLET
Core) were derived from a biopsy specimen that was procured from a triple negative primary
breast tumor and were passaged through immunodeficient animals in a method described
previously (Ding, Ellis et al.).

Cells were maintained in McCoy’s 5A media (Invitrogen,

Carlsbad, CA) supplemented with 10% FBS (Sigma, St. Louis, MO) and penicillin/streptomycin
(Invitrogen, Carlsbad, CA) in a 37o C humidified tissue culture incubator with 5% carbon dioxide.
Lentivirus containing the LC3-GFP fusion was obtained from C. Weihl (Washington University,
St. Louis, MO). The cells were transfected using a standard spinfection method with protamine
sulfate. After recovery, the cells were sorted on a BD Aria II High Speed Cell Sorter three times
with one-week recovery periods between each sort. The stable cell lines were then treated for 24
hours with DMSO (vehicle for rapamycin), rapamycin (100nM), nanoparticles (3.09x1010
particles/mL), or rapamycin-nanoparticles (3.09x1010 particles/mL = 100nM rapamycin). After
treatment, the cells were washed, fixed with paraformadehyde and imaged with a Zeiss LSM510
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microscope. GFP-positive puncta were counted by a blinded observer. Other treated cells were
prepared for transmission electron microscopy per standard protocols
For in vivo autophagic flux assessment, we utilized a recently developed autophagic flux
assay that measures turnover of LC3B-II in mouse skeletal muscle by comparing mice treated
with and without a potent blocker of autophagic protein degradation (colchicine) (Ju, Miller et
al.). Colchicine was administered over 48 hours in two doses (0.4 mg/kg) delivered
intraperitoneally, followed by diaphragm or heart tissue collection. Tissue homogenates were
probed as above.
A separate set of experiments using oral prednisolone as the active agent was conducted
to delineate potential mechanistic similarities between RNP and steroids with respect to their
effects on autophagy for an agent that is known to improve strength experimentally and in
patients. Four mdx mice were treated with oral prednisolone and four control mdx were treated
with vehicle for 42 weeks (starting at age 4 weeks), after which muscle tissues [tibialis anterior
(TA)] were extracted for autophagy measurements as above.

Statistics
Statistics were generated as noted below for selected ANOVA, t-test, and groupwise
comparison procedures using SAS software (SAS Institute, Cary, NC, USA) and the open-source
statistical package R (R Foundation for Statistical Computing, Vienna, Austria, http://www.Rproject.org).

5.5. Results

5.5.1. Rapid enhancement of global physical performance with RNP
None of the fourteen-week-old mdx and wild-type mice treated with nanoparticles
demonstrated apparent adverse effects from the treatment at any time point and all animals
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completed the study. Figure 21a shows that grip strength increased significantly when RNP
were employed as therapy (30% absolute increase in mean strength of group). Unexpectedly,
when nanoparticles (NP) alone were employed as therapy, grip strength exhibited a trend toward
a modest strength increase (Figure 21a) of 8%.
To determine whether the grip strength improvement was due to the drug alone, animals
were treated with oral rapamycin administered at 10x the equivalent nanoparticle i.v. dose to
account for an expected 10% oral absorption rate (Napoli, Wang et al. 1997; Crowe, Bruelisauer
et al. 1999; Stepkowski 2003; O'Reilly, McSheehy et al.). As shown in Figure 21a, the oral
rapamycin did not improve grip strength. Age-matched wild-type mice exhibited no significant
increase in grip strength when treated with rapamycin-loaded nanoparticles or oral rapamycin
(Figure 21b).
Figure 21c shows that over this washout interval, strength declined as anticipated. After the
repeat dosing of i.v. RNP, grip strength once again improved in the older mdx animals (p=0.008,
linear contrast model). No significant trend was observed in wild-type mice (Figure 21d).
Interestingly, RNP treatment of a cohort of 17-month-old mdx (n=8) mice treated for a month in
similar fashion revealed a more muted effect on strength (Figure 22a: p = 0.201, two-tailed
paired t-test).
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Figure 21. Rapamycin-loaded nanoparticle treatment improves strength in mdx mice.
a) Four weeks of treatment with rapamycin-loaded nanoparticles (RNP) delivered intravenously
significantly increased mean weight-normalized grip strength in 14-week old mdx animals (n=16)
vs. groups given plain nanoparticles (NP) IV (n=18), equivalent oral doses of rapamycin (n=6),
or oral placebo (n=6) (p=0.012, p=0.027, and p=0.016, respectively, using Fisher’s protected
least significant difference at 5% significance level). b) No significant difference in mean
strength was observed for age-matched wild-type mice given either NP (n=4) or RNP
intravenously (n=5) or oral rapamycin (n=6). c) The increase in weight-normalized strength in a
subset of mdx mice (n=8) treated with IV RNP occurred in both young (14-18 wk) and old (3438 wk) animals (p=0.008 using a linear contrast model comparing pre- to post-treatment
differences at a 5% significance level). Absolute values of the mean change in strength between
time points are shown in columns below trend data. d) Wild-type mice (n=5) given a similar
longitudinal treatment and drug-holiday exhibited no significant difference between pre- and
post-treatment strength (p=0.598). All bar graphs show mean values +/- s.e.m.
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Figure 22. Aged mdx mice show muted responses in grip strength after treatment with RNP, but
marked improvement in cardiac function commensurate with wild-type animals
a) Four weeks of treatment of 17-month-old mdx (n=8) yielded no significant increase in grip
strength (p=0.201, two-tailed paired t-test). b) LVEF in wild-type mice is greater than mdx
before treatment (p=0.016), as expected. c) Cardiac function significantly improved after RNP
therapy, irrespective of animal type (16% difference for mdx and 9% difference for WT;
p=0.024).
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5.5.2. Rapid enhancement of cardiac performance with RPN in aged mice
In the cohort of 17 month-old mdx and wild-type mice, one month of biweekly RNP versus
no treatment yielded two compelling findings: 1) LVEF in mdx was significantly lower than that
of wild-type mice before treatment (p=0.016) as expected (Figure 22b); and 2) LV ejection
fraction for RNP treated mice was 57 ± 2.9 %, and approximately 16% higher than that of nonetreated mdx mice (49 ± 2.5 %; p=0.024).

5.5.3. Nanoparticle tissue distribution
Results of fluorescence microscopy of fluorophore-labeled rapamycin and fluorophorelabeled lipids contained in the outer nanoparticle shell are shown in Figure 23. It is clear that the
particles penetrate heart tissue to deliver rapamycin locally (Figure 23). The labeled rapamycin
appears to achieve an even greater penetration into tissues than do the nanoparticles, arguing for
some degree of local rapamycin release and more complete passive diffusion. We note that the
use of the near-IR fluorophore avoids the problem of background autofluorescence, thereby
permitting confident assessment of the more diffuse penetration of rapamycin into muscle tissues
beyond the loci of nanoparticle deposition. The observation of diffuse rapamycin penetration into
tissues beyond the nanoparticle carriers (Figure 23) was further supported by analyzing both
blank slides and unstained muscle tissue specimens that were microscopically digitized at the
same settings to rule out background signals of any type that might have overlapped with the
rapamycin signal, and none were observed (data not shown).
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Figure 23. Nanoparticles and rapamycin
are delivered to cardiac muscle in mdx
animals.
Nanoparticle lipid (rhodamine, displayed as
blue) and rapamycin (Cy7.5, labeled as red)
are colocalized in mdx cardiac tissue.

5.5.4. Effects on skeletal and cardiac mTOR and autophagic processes
To further demonstrate that the drug reaches muscle tissue and then acts on a known target,
lysates from the muscle were probed for phosphorylated S6. S6 is downstream of mTORC1, so
that blocking mTORC1 with rapamycin should cause a decrease in pS6 levels. Indeed, in
diaphragm, triceps, biceps, and gluteus, S6 levels were decreased in mdx animals treated with
rapamycin-loaded nanoparticles when compared to mice treated with nanoparticles alone (Figure
24a). Interestingly, the nanoparticles themselves caused a modest increase in pS6 levels when
compared with saline treated animals. Thus, the particle itself may induce signaling through
mTORC1, but adding rapamycin to the particle then decreases the level of signaling, yet does not
cause a return to baseline levels.
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Our data confirm that the mdx mouse harbors a defect in autophagy in muscle tissues, as
there is an increase in p62 protein (Figure 24b) with no difference in p62 transcription (Figure
24c).

This expression pattern suggests that p62 is not being consumed in the process of

autophagy in the mdx animal as it is in the wild-type animals. Further, BNIP3, a protein that is
known to trigger autophagy, is found at lower levels in mdx animals when compared to wild-type
(Figure 24b, c). Additional in vivo confirmation of the effects of rapamycin nanoparticles on
autophagy revealed that basal autophagic flux was diminished in mdx mouse heart as
demonstrated by comparing the change in LC3II protein levels with and without colchicine
treatment (Figure 24d).
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Figure 24. mdx animals exhibit a defect in autophagy that is restored by nanoparticle treatment.
a) RNP cause a decrease in S6 levels in mdx animals when compared to NP treatment. However,
compared to saline treatment, the NP increased S6 phosphorylation in all muscle groups tested, a
trend not observed in the muscles from wild-type animals. b) Proteins were extracted from mdx
and age-matched control animal muscle. Western blot analysis for p62 (n=5 per group) and
BNIP3 (n=3 per group) reveal a defect in autophagy as mdx animals exhibited higher levels of
p62 and lower BNIP3 when compared to wild-type (Student’s t-test at 5% significance level).
Myosin was used as the loading control. c) RNA was isolated from the tibialis anterior muscle
of age matched mdx (n=5) and control mice (n=3). QPCR was performed and normalized to
GAPDH. Graph demonstrates fold change in the following transcripts vs. control: there was no
change in p62, BNIP3 or beclin. Beta 2 microglobin is increased as expected, because it is part
of MHCI, which is known to be upregulated in mdx muscle. Actin levels (normal) serve as an
internal control. d) Representative Western blots demonstrate that both nanoparticle (NP) and
rapamycin-loaded nanoparticles (RNP) increase the levels of LC3B-II in the mdx animal,
whereas saline treated animals exhibit a low level of LC3B-II expression, even when blocked
with colchicine. Scatter plots show results from individual animals.
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Additional probing of the tibialis anterior (TA) and heart muscle in the 17 month-old mice
treated for 1 month with RNP was performed to assess the autophagic responses. Figure 25a
illustrates significant effects of RNP in TA on p62 (decrease), BNIP3 (increase), and LC3II
(increase). Figure 25b confirms that RNP also enhanced autophagy in the heart in the same
manner. Figure 25c shows autophagic responses to prednisolone in the TA of mdx mice, where
changes in p62, BNIP3, and LC3II are all similar in direction and magnitude to those reported
above for RNP, further suggesting that autophagy responses to either RNP or steroids in the mdx
represents a likely candidate mechanism for the observed augmentation of muscle strength and
cardiac function. Taken together, these data point to a rapid and widespread induction of
autophagy in diverse muscle tissues after RNP treatment.
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Figure 25. Rapamycin nanoparticles alter autophagic biomarkers in heart and skeletal muscle of
mdx mice similar to that after steroid therapy.
a) Tibialis anterior (TA) muscle in 17-month-old mdx mice treated for 1 month with RNP
exhibited significant effects of RNP on p62 (decrease), BNIP3 (increase), and LC3II (increase).
b) Cardiac data confirms that RNP also enhance autophagy in the heart in the same manner. c)
Young mdx mice given 42 weeks of steroid therapy show similar autophagic responses in the TA
muscle.

5.5.5. Tissue structural responses
The amount of collagen within skeletal and cardiac muscles (Figure 26a-d) was not
different between the treatment groups (p=0.900 for diaphragm using mixed model nested
ANOVA, p=0.664 for heart using unpaired two-tailed t-test). Figure 26e demonstrates no
significant difference between creatine kinase (CK) levels in saline treated animals when
compared to those treated with NP or RNP (p=0.682, one-way ANOVA). From these data, it
does not appear that the nanoparticles are exerting their beneficial effect on strength by altering
the turnover of myocytes or the replacement of myocytes with collagen in the short term, as
might be expected after only 8 doses of therapy.
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Figure 26. Intravenously injected nanoparticles do not affect short-term muscle cell destruction
or fibrosis.
a) Masson trichrome stains performed on diaphragm sections and visualized with light
microscopy (200x) showed increased fibrosis (blue) for mdx animals relative to WT. b) No
significant difference occurred over the short 4 week test interval in mdx collagen levels after
treatment with either rapamycin-loaded nanoparticles, plain nanoparticles, or saline (mixed
model nested ANOVA, p=0.90). c) Picrosirius red stains of mdx mice show diffuse
heterogeneous fibrosis with d) no significant difference (p=0.664) when treated with RNP. e)
Serum creatine kinase levels for mdx mice exhibited no significant difference after treatment
with either RNP, NP, or saline (ANOVA, p=0.71). All bar graphs show mean values +/- s.d.

5.6. Discussion
The present findings indicate that rapid improvement in physical performance of either
skeletal and cardiac muscle can be achieved after only 8 doses of RNP in conjunction with
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augmented autophagy.

In contrast, oral rapamycin in pharmacological doses exerted no

significant effect on strength within the same interval. The observations that the improvement
in grip strength is repeatable after a drug holiday in the same mice, together offer further support
for the salutary role of RNP on enhancing autophagy, global physical performance, and cardiac
function in muscular dystrophy. The muted response to strength testing in aged mdx as compared
to the clear enhancement in cardiac function reveals a not unexpected limitation on what might
be achievable after initiation of therapy late in the disease process.
Recently published work suggests that autophagy induction may be beneficial to mdx animals,
whether induced by rapamycin or by dietary protein reduction (Pauly, Daussin et al. 2012).
Moreover, a decrease in autophagic flux in vivo has been previously reported for an animal
model of Bethlem myopathy and Ullrich congenital muscular dystrophy due to mutations in
Col6a-/-

suggesting

that

disturbed

autophagy

might

occur

in

other

muscular

dystrophies (Grumati, Coletto et al.), yet this mechanism has not been evaluated previously for
aged DMD/mdx, as we show here. Furthermore, no prior studies have demonstrated
improvements in global physical performance in vivo or cardiac function after rapamycin
therapy in aged animals that might be attributable to enhanced autophagy.
The observation of a muted response to short term RNP in the older 17-month-old mice for
skeletal muscle performance in the face of a clear improvement in myocardial LVEF and clear
induction of autophagy points out certain divergent pathophysiological features of the disease. It
is recognized that the heart disease in DMD appears later than the skeletal muscle weakness, but
emerges ultimately as a major source of morbidity and mortality. Why heart muscle is relatively
more resistant to disease progression than is skeletal muscle despite continuous contractile
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activity remains unknown. Interestingly, the disease in the heart evolves regionally (e.g.,
base>apex) despite the ubiquitous loss of the dystrophin (Chapter 2~3).
Although recent retrospective analyses of steroids in DMD are highly suggestive of a
beneficial long-term effect on cardiac function (Schram, Fournier et al. 2013), the present data
are the first to illustrate such rapid improvement with systemic rapamycin in a prospective trial
invoking a unique mechanism of action. Parenthetically, our observation of improved LVEF
even in wild type subjects (Figure 22) accords with a recent report by Flynn et al. noting better
LVEF in 24 month-old female nondystrophic animalds treated continuously for 3 months with
rapamycin in an oral "high delivery" formulation (Flynn, O'Leary et al. 2013). The attenuated
response of skeletal muscle strength to RNP in older mdx in our study suggests either that longer
term or more aggressive therapy might be required at this stage to enhance strength, or that
certain limitations may exist for this (or even any) form of therapy, neither of which is especially
surprising. Interestingly, Flynn et al also reported that oral rapamycin increased endurance but
not intensity of activity in 24 month-old female mice, suggesting a muted effect on strength
improvement in older subjects in general, which accords with our observation on grip strength
for the 17-month old dystrophic mice (Flynn, O'Leary et al. 2013). Regardless, the ability of
RNP to rapidly improve cardiac performance suggests that a single agent might be useful.

The cumulative dose of rapamycin administered to the animals in the rapamycin-loaded
nanoparticle treatment group was within the limits of recommended oral doses for patients
receiving immunosuppressive therapy when accounting for ~20% oral absorption in humans
(Ferron, Conway et al. 1997). The rationale for comparing intravenous nanoparticle rapamycin
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therapy with oral rapamycin delivery stems from the conventional practice of oral delivery as
standard of care in patients requiring immune suppression, which is known to be effective and
well tolerated at the recommended dose levels. We accounted for the well-known and previously
reported bioavailability for oral dosing (rough estimates: ~10% in mice (Napoli, Wang et al.
1997; Stepkowski 2003; O'Reilly, McSheehy et al. 2010) by augmenting the doses that were
delivered to mice by oral gavage to ensure adequate delivery. Typical clinical maintenance
dosing for oral delivery of sirolimus in organ-transplant scenarios for body mass greater than 40
kg is 2 mg/day (Rapamune, Pfizer Inc, Philadelphia, PA). Assuming 20% bioavailability, this
equates to approximately 0.4 mg of rapamycin in circulation per day, or approximately 0.006
mg/kg/day for a 70 kg patient. The maximum permissible daily dose of rapamycin is 40 mg,
which equates to 0.11 mg/kg/day. Mice treated with RNP i.v. in the current study were given
0.067 mg/kg rapamycin biweekly for a total of 8 times over 4 weeks, or the equivalent of 0.002
mg/kg/day, within the clinical bounds for regular therapeutic use.
The intravenous dose used here was approximately 7-fold less than the calculated absorbed
oral dose administered to mdx mice by Eghtesad and colleagues to improve muscle
histopathology (Eghtesad, Jhunjhunwala et al.). Moreover, Eghtesad also reported that oral or
injected rapamycin exerted no affect on the TA muscle, in contrast to the marked upregulation of
autophagy reported here in the TA after RNP therapy (see Figure 26). Taken together, these data
indicate that at clinically relevant doses of oral rapamycin for mdx animals, which scale up to 4–
fold greater than the recommended oral dose for patients, no improvement in skeletal muscle
strength might be expected. In contrast, a clinically approved cumulative dose of rapamycin
administered in NP formulations rapidly elicited marked improvement in both global physical
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performance and cardiac function after only eight i.v. treatments, which could represent an
advantage for periodic, short-term dosing.
Furthermore, nanoparticles alone did not increase autophagic flux in wild-type mice whereas
rapamycin nanoparticles did. While rapamycin is known to promote autophagy via an mTOR
dependent mechanism, the mechanism by which nanoparticles influence autophagy is not known.
It is intriguing that nanoparticles were unable to enhance autophagy in wild-type mice with
presumably normal sarcolemmal structure whereas in mdx mice that have defective sarcolemmal
integrity due to dystrophin mutations, nanoparticles were effective.
Rapamycin also exhibits mTORC1-independent effects when it binds to FKBP12 on the
ryanodine receptor. Previous studies suggest that binding of rapamycin disrupts the ryanodine
receptor’s functions and therefore would be expected to elicit dysfunctional calcium handling
(Ahern, Junankar et al. 1997; Avila, Lee et al. 2003). However, in mdx animals, the ryanodine
receptor itself appears to be dysfunctional (Bellinger, Reiken et al. 2009). It may be the case that
the addition of rapamycin acts to modulate some of these receptors in a favorable manner and
effect more normal calcium handling or else acts to decrease the expression of the receptors as
has been previously reported (Avila and Dirksen 2005).
The effectiveness of nanoparticles and rapamycin nanoparticles for stimulating autophagy in
mdx mouse muscle mirrors that of their efficacy in rapidly improving grip strength and cardiac
function. Although these data may not establish absolute proof of cause and effect for the
relationship between autophagy and strength, they suggest an intriguing candidate mechanism
for the decline in strength that might be manageable clinically with an approved drug and a new
delivery system.
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Although the exact mechanism responsible for rapamycin's entry into muscle tissue remains
to be clarified, the effect on autophagy is clear and seems dependent on nanoparticle depot
delivery, because oral therapy is ineffective at the doses that were administered. The sustained
presence of nanoparticles and rapamycin in skeletal and cardiac tissues is clear from the

19
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spectroscopy and the fluorescence imaging data. Prior pharmacokinetic studies in both rabbits
and mice using PFC nanoparticles have confirmed a clearance halftime (or, elimination half-life)
of ~3-5 hours in normal mice and rabbits used in various cancer models (Hu 2007; Soman,
Baldwin et al. 2009), irrespective of molecular targeting, suggesting that there should be ample
opportunity to penetrate into the damaged tissues. We previously have demonstrated rapid
permeation of these nanoparticles in other situations where leaky or disrupted vasculature
pertains, such as advanced atherosclerosis in cholesterol fed rabbits, and even in atherosclerotic
human carotid endarterectomy specimens (Cyrus, Zhang et al. 2008; Zhang, Zhang et al. 2011).
It is instructive to note that in dystrophic subjects, recent and prior publications have pointed out
the widespread vascular dysfunction and damage that permits egress of circulating components
into muscle interstitium (Vidal, Ardite et al. 2012). Dystrophic subjects also harbor defects in
vascular endothelium that render lining cells susceptible to apoptosis and impaired angiogenesis
(Palladino, Gatto et al. 2013), creating a situation of barrier dysfunction that even applies to the
blood-brain barrier (Lien, Mohanta et al. 2012).
Regarding the translational potential of this approach, we note that these beneficial effects on
both heart and skeletal muscle were achieved at a cumulative dose of rapamycin that accords
with clinically recommended dosing.

Although the side effects of rapamycin on glucose

tolerance, weight gain, blood pressure, and immune responsiveness are recognized, the drug is
generally well tolerated over many years by patients with organ transplantation. The fact that
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both prednisone and rapamycin appear to induce autophagy as a possible mechanism of action
raises the possibility that the potential deleterious consequences of either agent might be
mitigated if used in lower doses in combination, or at least if RNP could be employed for a
steroid sparing action.
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6.

Chapter 6: Conclusion
6.1. Summary of major findings
In this study, we observed that:
1. Myocardial sheets can be imaged in fresh/unfixed/unstained heart with photoacoustic
image microscopy, indicating that sheet structures are not just dehydration artifacts as
criticized in earlier histology studies (Zhang, Cheng et al. 2012).
2. By using Langendorff perfused heart preparations with DTI, viable myocardial sheet
function can be imaged without motion-artifact. We observed that sheet dysfunction is
manifest in diastole but not in systole, indicating a relaxation problem with mdx hearts
(Chapter 2).
3. Fibrosis and sheet dysfunction evolve regionally in the mdx mouse heart at the base
despite the lack of dystrophin in every cardiac cell, indicating that all other observed
concomitant pathologies contributing mechanistically to the cardiomyopathy are
secondary and developmental rather than primary drivers of the disease process (Chapter
2).
4. Sheet dysfunction is reversible by lowering the perfusate calcium concentration, i.e., mdx
heart exhibits calcium dependent relaxation-failure (Chapter 2).
5. At least two tensor invariants are needed to describe the anisotropy of the diffusion tensor,
although most related research has reported only fractional anisotropy for reasons of
simplicity. Here we demonstrate how the mode of anisotropy and fractional anisotropy
provide complimentary information regarding myocardial architecture anisotropy in mdx
mice (Chapter 3).
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6. Abnormal calcium transients are stretch activated and evolve regionally first at the base,
indicating that the lack of dystrophin triggers calcium mishandling more quickly at the
base but not the apex, especially when stretched (Chapter 4).
7. Fibrosis, sheet dysfunction, and calcium mishandling are all more severe in older mdx
mice (16 month old) than in young mice (3 month old).

6.2. Future works:
6.2.1. Intervention for calcium mishandling and autophagy in DMD
In Chapter 2, we found that mdx sheet dysfunction is regional, progressive and calcium
dependent. Therefore, we hypothesized that if we correct the calcium mishandling, we could
ameliorate sheet dysfunction. This was carried out in whole hearts by adjusting perfusates with
good results, which is compatible with other strategies mentioned above to ameliorate calcium
mishandling and systolic dysfunction by genetically engineered approaches. In the case of sheet
dysfunction that produces diastolic abnormalities early in the course of heart disease, which itself
may predispose to further damage by "stiffening" the heart, even earlier metrics of beneficial
interventions might be observed via restoration of sheet mechanics. Although steroids are
currently the most effective treatment for DMD patients, their efficacy decreases after prolonged
treatment (Markham, Spicer et al. 2005). Therefore, cocktail therapies targeting different
pathological mechanisms with the use of steroids, current calcium approaches, ACEi, autophagy,
and beta-blockers might be desirable in the hopes that gene therapy might emerge as a first line
therapy. The proposed DTI measured sheet angle could offer a surrogate for the efficacy of such
interventions.
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6.3. Remarks on dystrophin function
Here it is instructive to quote from other author's insights into the progressive regional nature
of dystrophin-null cardiomyopathy (Judge, Kass et al. 2011):
“One hypothesis regarding the cause of cardiomyopathy for individuals with reduced or
absent dystrophin is based simply on a structural deficiency. Since dystrophin is part of the
DGC, its primary role may be to hold this complex together. When deficient or absent, the
dystrophin-associated glycoprotein complex may deteriorate due to the hemodynamic stress
associated with normal left ventricular function. Evidence for this includes the loss of several
components of the DGC from the plasmalemma when dystrophin is absent. If this were the
only contribution of dystrophin to normal cardiac function, then one would anticipate that
cardiac dysfunction would be more uniform with regard to its age of onset and severity in
DMD. … Another hypothesis for cardiac dysfunction in DMD and BMD posits that
dystrophin and its associated complex of ECM glycoproteins play a regulatory role. ”
Then one might ask, what regulatory function might dystrophin have? And furthermore, why
would this be different at the base and apex? In fact, nitric oxide, SMAD, or TGF-beta pathways
all are reported to be affected by dystrophin-null conditions (Chao, Silvagno et al. 1998;
Heydemann, Ceco et al. 2009; Goldstein, Kelly et al. 2011), but it is still unclear what the role of
dystrophin in those pathway might be and whether these problems are primary or secondary to
myocyte damage. For example, does dystrophin turn on NO pathway to increase coronary flow
in response to certain mechanical input? If dystrophin is a switch, what turns it on in response to
what stimulus? The function of dystrophin can be discussed from an evolutionary standpoint.
First, dystrophin is an ancient protein that exists even in drosophila and sea urchin (Neuman,
Kaban et al. 2001; Kucherenko, Marrone et al. 2011). Morris 1977 found that “In Xenopus heart,
little or no dystrophin was found on Western blots but the dystrophin-related protein, utrophin,
was abundant. … In skeletal muscle, however, Xenopus resembles mammals in expressing
dystrophin at the sarcolemma and very little utrophin” (Morris 1997). Based on the fact that
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Xenopus, an amphibian, does not express dystrophin in the heart, one could hypothesize that
dystrophin was adapted in mammal hearts for some unknown function that is not required in
amphibian hearts. Therefore, a comparative study on heart function and dystrophin distribution
in base vs apex of the heart could shed lights on dystrophin’s mysterious function. It also would
be telling to investigate dystrophin’s expression in heart development, especially to focus on
different locations exhibiting different stress levels in embryological development; and at
different development stages such as before and after the foramen ovale closes. It is possible that
cardiac dystrophin’s regional expression may change dramatically as a marked redistribution of
cardiac stress occurs during and after birth, in light that dystrophin protein was not detected in
early embryonic days until prenatal stage in rat (Tanaka and Ozawa 1990).
It also is curious why the apex is spared. Recall the Laplace law (eq41).
𝑆=

𝑃
2

𝑟

×ℎ

…...

eq41

Stress in the ventricular wall (S) is proportional to transmural pressure (P) and the ratio between
radius (r) to wall thickness (h) (Warren W. Burggren 1997). Indeed, Kim el al have reported ~30%
higher wall stress at the base of anesthetized canine heart (Kim, Min et al. 1985). In 1998, using
markers and intraventricular pressure catheters, DeAnda et al also estimated up to four times
higher wall stress in base compared to apex in awake dogs (DeAnda, Komeda et al. 1998),
agreeing with the prediction made with Laplace law.
Evolution in some respects is an adaptation to stress. 360 Million years ago, fish evolved
into amphibians and faced new challenges in a terrestrial environment, including air exchange,
dehydration, and gravity. In water, animal’s body weight is supported by buoyancy, which is not
operative on land. Therefore, gravity might contribute to the fact that the largest extant land
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animal, the African bush elephant (4.9 tons, 6m)9, is 22 times lighter than the largest marine
animal blue whales (110 tons, 25.5m)10. Humans assume that living on the land is simple, but
living in the ocean is challenging. But in evolution, the ability to deal with the land environment
is emergent as opposed to encoded. Indeed, terrestrial animals likely must “pay” for their body
size with certain limiting adaptations. Because area-dependent functions increase less rapidly
than volume-dependent functions as an organism’s size increase, severe scaling constraints may
result as land organisms evolved to larger size (Schmidt-Nielsen 1984). For example, assuming
no allometry, body weight is proportional to the body length to the power of three, while the
muscle cross section area11 is proportional to body length to the power of two. Therefore, the
stress (force/area) in muscle, in order to bear the body weight of the land animal, is proportional
to the “body weight divided by muscle cross section area,” which is body length to the power of
one. Therefore, we might assume that a 180 cm tall man experiences twice the stress in the calf
as does a 90 cm tall man, all else being equal.
It is logical then that the fundamental function of dystrophin is to protect muscle in high
stress environment. Myocardial sheet/calcium transient abnormalities and fibrosis manifest
more at base but not apex in 16 month old mdx mice (Chapter 2), consistent with higher stress at
the base than apex (DeAnda, Komeda et al. 1998). Furthermore, myocardial sheet abnormalities
and fibrosis do not appear in 3 month old mdx mice, which have 15% smaller heart radius.
Potentially, the smaller radius resulting in smaller stress spares the heart from abnormalities at

9

African bush elephant. Animal Diversity Web.
http://animaldiversity.ummz.umich.edu/site/accounts/information/Loxodonta_africana.html
10
Blue Whale. The Marine Mammal Center. http://www.marinemammalcenter.org/education/marine-mammalinformation/cetaceans/blue-whale.html#.UjIVGcZ6ZRs
11
Vertebrate striated muscle exerts nearly a constant peak tensile stress, ~200k Pa = 2M dyn/cm2, among
species. Biewener, A. A. (1989). "Scaling body support in mammals: limb posture and muscle mechanics." Science
245(4913): 45-48.
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earlier ages. Therefore, young mice do not exhibit a cardiac, or even much skeletal dystrophic
phenotype, despite the fact that all tissues lack dystrophin before birth.
DMD patients (dystrophin-null) experience the onset of symptoms before two year old
and become wheelchair bounded between ages 7 and 13. On the other hand, BMD patients
(dystrophin-deficient) have much more benign progress of disease. BMD patients have their
onset of symptoms between ages 2 to 21, and become wheelchair bound between ages 22 and 51
(Emery and Skinner 1976). That is, the partially expressed dystrophin in BMD patients is still
able to protect the increased stress from the growing body size until age 22 to 51. In a 111 DMD
patients study, height was found to be correlated with disease progression (disability accessed by
the Vignose scale) with a correlation coefficient of 0.352 (p<0.001), indicating that small stature
might protect against the ravages of DMD. A classic paper that has been cited 870 times has
reported sarcolemma damage is linearly correlated with stress (force/area cross section). That is,
mdx diaphragm muscle shows more damage than does wildtype diaphragm muscle (Petrof,
Shrager et al. 1993). Similarly, cardiomyocytes of mdx mice are more vulnerable to mechanical
stress induced by isoproterenol and aortic banding (Danialou, Comtois et al. 2001) than are
normal myocytes. Indeed, anti human growth hormone (HGH) therapy was found to be effective
in DMD patients (Zatz, Betti et al. 1986). Four case reports suggested that patients with
deficiency in both HGH and dystrophin show slow or no progress of muscular waste until the
administered to solve the short stature (Zatz, Betti et al. 1981; Zatz and Betti 1986; Ghafoor,
Mahmood et al. 2003; Calcaterra, Malvezzi et al. 2013). However, an HGH inhibitor, mazindol,
fails to inhibit the growth over longer times as suggested by Zatz (Zatz, Rapaport et al. 1988):
“However, the recent report of two new DMD patients with short stature and a benign
evolution of the dystrophic process (Passos et al., 1988; Wu et al., 1988) and the
observation of wide variability in the progression of the disease in DMD/BMD patients
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with apparently the same DNA deletions suggests that secondary factors, such as
growth hormone (GH) may be implicated in the progression of the disease (Infante and
Huszagh, 1988; Malhotra et al., 1988).”
That is, Zatz speculated GH itself might have modified the disease. It appears rather more
likely that the GHheightstress cascade is the operative factor in modifying the disease.
It is known that, in DMD patients, calf muscles fail to perform normal function first, then
the diaphragm fails (Bach 1992; Hamada, Ishikawa et al. 2011). The cardiomyopathy emerges
last (Fayssoil, Nardi et al. 2010). It is natural to ask: among the calf, the diaphragm, and the heart,
which muscle bears the most stress (force/area)? Does the failure sequence in DMD muscles
correspond to the ranking of stress? To the best of my knowledge, there is no study comparing
stresses in these three muscles together in DMD nor in mdx mice. However, the following
summarizes the existing data.
Thorpe et al found normal young adults (~1.7m ~73kg) have peak stresses of 100 kNm-2
during high jumps and 150kNm-2 during 4ms-1 running in calf (gastrocnemius and the soleus)
(Thorpe, Li et al. 1998). Using the reported height of age 8 DMD patients, ~1.4m (Beenakker, de
Vries et al. 2002), and assuming no allometry and stress is roughly proportional to the height, we
can estimate the high jump and running stress in a DMD boy are 82 and 123 kN/m2 ,
respectively, which should be the upper limit of stress in DMD patient calf, because they have
pseudo-hypertrophic calf and less contractility due to fibrosis.
Stress data in calf muscles in a standing posture in normal humans are scanty. However,
Morse et al have reported isometric maximum stress of calf muscles in young (131 kN/m2 , age
25, 1.7m, 79 kg ) and elderly (92 kN/m2 , age 74, 1.7 m, 78 kg) normal people (Morse, Thom et
al. 2005). Taking elderly subjects stress data and assuming no allometry, a DMD patient of 1.4 m
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height should have an isometric maximum stress of 92*1.4/1.7= 75 kN/m2 in calf. Although
assuming no allometry may not be true, it is the best approximation devoid of additional calf
geometry information. I cannot find any literature addressing the fascicle force and physiological
cross-sectional area in calf muscles of DMD patients. However, from the above two literature
sources, I estimate that standing calf stress in DMD patient is smaller than 75 kN/m2.
mdx mice diaphragm strips were reported to exert maximum tetanic stress of 91~136
kN/m2 in ex vivo experiment (Lynch, Rafael et al. 1997; Lynch, Hinkle et al. 2001). In vivo
measurement of diaphragm stress were not available in literature, to the best of my knowledge,
probably because the thin anatomical geometry of the diaphragm limits the observation
opportunity. However, Hughes et al used two balloons placed in the stomach and esophagus to
measure the transdiaphragmatic pressure in normal adult humans and reported a value of 143 cm
H2O (105 mmHg) (Hughes, Polkey et al. 1999). Meanwhile, Beck reported a maximum
transdiaphragmatic pressure of 7.6 cmH2O ( 5.6 mmHg ) in DMD patients with advanced stage
disease (N=8, mean age 25) (Beck, Weinberg et al. 2006). Although the in vivo stress of the
diaphragm was not reported, it is not unreasonable to assume that the diaphragm exhibits
comparable or higher stress than does heart wall, because the thickness of diaphragm (1.74 mm
thick in 10 year old DMD patients; 1.45 mm in normal controls (De Bruin, Ueki et al. 1997))
is >3 times thinner than heart wall ( 4.8 mm in diastole; 8.7 mm in systole (Goldberg, Feldman et
al. 1980)). Diaphragm has comparable maximal transmural pressure as with the heart (105
mmHg vs 120mmHg). Meanwhile, the diaphragm has much larger radius of curvature.
Numerical values of stress in normal adult human heart wall are more abundant. Normal
wall stress was reported to be 18~33 kN/m2 in systole and 2~3 kN/m2 in diastole (Hood, Rackley
et al. 1968; Grossman, Jones et al. 1975). In DMD, one study reported 23 DMD patients with
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mean age of 8 have a wall stress of 49 (Markham, Kinnett et al. 2008). Unfortunately. this paper
ignored the units of wall stress.
In conclusion, values from literature suggest that the calf might be stressed more in 1.4m
tall boys than the heart (75 vs 18~49 kN/m2). I speculate that the diaphragm might experience
even higher stresses than the heart because of the comparable transmural pressures in the face of
thinner thickness, and larger curvature radius, but there are no available data reported. After
reviewing all of the published values of stresses, it would not be surprising if the stress ranking is
actually: calf > diaphragm > heart, which might explain the temporal sequence of failing muscles
in DMD patients.
Deconinck

proposed

a

damage

pathway

initiating with the lack of dystrophin (Figure 27)
(Deconinck and Dan 2007). However, this simplistic
model fails to incorporate the supposition that it might
be stress itself that modifies the degree of damage in
different parts of the heart and skeletal muscles at
different ages and body sizes.

Figure 27. mdx dystrophy pathway proposed by
Deconinck et al. (Deconinck and Dan 2007)
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Hauser, Whitehead, and Yeung suggested that “NADPH oxidase is a major source of
reactive oxygen species in dystrophic muscle and its enhanced activity has a stimulatory effect
on stretch-induced Ca2+ entry, a key mechanism for muscle damage and functional impairment.”
(Hauser, Hoger et al. 1995; Whitehead, Yeung et al. 2010; Yang, Chin et al. 2013) That is, these
authors have recognized the stretch-induced damage is a factor complementing the lack of
dystrophin. Therefore, I propose an updated damage pathway in Figure 28, proposing that the
stress in muscle is the activation factor operating on the ubiquitous lack of dystrophin.

Figure 28. Hypothesized mdx dystrophy pathway.

To ameliorate DMD, beta blockers, ACE inhibitors, and growth inhibition have all been
reported to slow DMD progression (Zatz, Betti et al. 1986). In the hypothesis proposed in this
Chapter, these therapies work because they all modulate stresses in muscles. However, none of
these can have a long-term curative effect, leaving more revolutionary genetic and
pharmaceutical strategies desirable.
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7.

Appendices
Principle of MRI
-Physics
In the view of classic physics, hydrogen nuclear spins, and thus creates magnetic moment,
which aligns to surrounding magnetic field (B0) in the same way compass points to the North
Pole. 12 Instead of aligning statically with B0, the magnetic moment would precess about the B0
direction. The precession frequency, ω, is named Larmor Frequency and defined by ω = γ B,
where γ is gyromagetic ratio, depending on nuclear species. While nuclei spin reaches steady
state of precession toward B0, we can excite the steady state temporarily with an added magnetic
field (B1), causing the nuclear spin to deviate from its steady state orientation.13 After the B1 was
stopped, nuclear spin will align back to the B0 direction and release energy in a form of
detectable radio frequency magnetic waves (called free induction decay, FID), which can be
recorded and signal processed for imaging purposes.

-Imaging
Invented in 1952, MRI allows scientist to acquire FID and forms images to provide
structural and functional information. Recall the Larmor Frequency, ω = γ B, which is
proportional to the magnetic field strength B, allowing us to control the ω by varying the B. For
imaging purpose, we are interested in encode spin at different spatial locations with different ω.
Therefore, a gradient of magnetic field, Gx, was applied along x direction on top of the B0,
making the ω a function of x, that is, ω(x)=B0 + x ·G, therefore, the recorded FID carries spatial
information in different frequencies, allowing imaging reconstruction through inverse Fourier
transform. This imaging technique is called frequency encoding. Please refer to book in footnote
11 for more information. By turning on-off radio frequency pulses and gradients at specific time
and direction, we would be able to form images to suit specific purpose. The specific
timing/direction/strength of radio frequency pulses and gradients are call pulse sequence, which
determines the sources of contrast and properties of the images.

The mechanism of nuclear spin is beyond scope, please refer to “Questions and Answers in Magnetic Resonance
Imaging”, 2000, by Allen D. Elster.
13
For detailed physics explanation, see “Spin Dynamics: Basics of Nuclear Magnetic Resonance” by Malcolm H.
Levitt (2008)
12
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Supplemental tables

Table 2.Post Hoc Multiple Comparisons of |β| in 16 month old mice
Bonferroni
95% Confidence Interval

Mean Difference
Dependent Variable

(I) group

(J) group

magB_slc1

1

2

2.4033

2.01043

1.000

-3.6447

8.4514

3

1.0321

2.01043

1.000

-5.0159

7.0802

4

6.7905*

2.01043

.023

.7425

12.8386

1

-2.4033

2.01043

1.000

-8.4514

3.6447

3

-1.3712

2.01043

1.000

-7.4193

4.6768

4

4.3872

2.01043

.266

-1.6608

10.4353

1

-1.0321

2.01043

1.000

-7.0802

5.0159

2

1.3712

2.01043

1.000

-4.6768

7.4193

4

5.7584

2.01043

.067

-.2896

11.8065

1

*

-6.7905

2.01043

.023

-12.8386

-.7425

2

-4.3872

2.01043

.266

-10.4353

1.6608

3

-5.7584

2.01043

.067

-11.8065

.2896

2

-.6827

2.36177

1.000

-7.7877

6.4223

3

-1.3088

2.36177

1.000

-8.4138

5.7962

4

4.9628

2.36177

.311

-2.1422

12.0677

1

.6827

2.36177

1.000

-6.4223

7.7877

3

-.6261

2.36177

1.000

-7.7311

6.4789

4

5.6455

2.36177

.177

-1.4595

12.7504

1

1.3088

2.36177

1.000

-5.7962

8.4138

2

.6261

2.36177

1.000

-6.4789

7.7311

4

6.2715

2.36177
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-.8334

13.3765

1

-4.9628
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.311

-12.0677

2.1422

2

-5.6455

2.36177
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-12.7504

1.4595

3

-6.2715

2.36177

.104

-13.3765

.8334

2

-.9798

2.26177

1.000

-7.7840

5.8244

3

-.3786

2.26177

1.000

-7.1828

6.4255

4

*

8.3630

2.26177

.012

1.5588

15.1672

1

.9798

2.26177

1.000

-5.8244

7.7840

3

.6012

2.26177

1.000

-6.2030

7.4053

4

9.3428*

2.26177

.005

2.5387

16.1470

1

.3786

2.26177

1.000

-6.4255

7.1828

2

3

4

magB_slc2

1

2

3

4

magB_slc3

1

2

3

(I-J)

Std. Error
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Sig.

Lower Bound

Upper Bound

4

magB_slc4

1

2

3

4

magB_slc5

1

2

3

4

magB_slc6

1

2

3

2

-.6012

2.26177

1.000

-7.4053

6.2030

4

8.7416*

2.26177

.008

1.9375

15.5458

1

*

2.26177

.012

-15.1672

-1.5588

2

*

-9.3428

2.26177

.005

-16.1470

-2.5387

3

-8.7416*

2.26177

.008

-15.5458

-1.9375

2

-1.3733

2.27890

1.000

-8.2290

5.4824

3

-.3664

2.27890

1.000

-7.2221

6.4893

4

5.1555
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1
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-5.4824
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3
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-5.8488

7.8626

4

6.5288

2.27890

.067

-.3269

13.3845

1

.3664

2.27890

1.000

-6.4893

7.2221

2

-1.0069

2.27890

1.000

-7.8626

5.8488

4

5.5219

2.27890

.166

-1.3338

12.3776

1

-5.1555

2.27890

.228

-12.0112

1.7002

2

-6.5288

2.27890

.067

-13.3845

.3269

3

-5.5219

2.27890

.166

-12.3776

1.3338

2

.4927

1.96992

1.000

-5.4334

6.4189

3

.3064

1.96992

1.000

-5.6198

6.2325

4

5.6741

1.96992

.065

-.2520

11.6003

1

-.4927

1.96992

1.000

-6.4189

5.4334

3

-.1863

1.96992

1.000

-6.1125

5.7398

4

5.1814

1.96992

.109

-.7448

11.1076

1

-.3064

1.96992

1.000

-6.2325

5.6198

2

.1863

1.96992

1.000

-5.7398

6.1125

4

5.3677

1.96992

.090

-.5584

11.2939

1

-5.6741

1.96992

.065

-11.6003

.2520

2

-5.1814

1.96992

.109

-11.1076

.7448

3

-5.3677

1.96992

.090

-11.2939

.5584

2

1.4707

2.06307

1.000

-4.7357

7.6771

3

1.4960

2.06307

1.000

-4.7104

7.7025

4

4.2457

2.06307

.338

-1.9607

10.4521

1

-1.4707

2.06307

1.000

-7.6771

4.7357

3

.0253

2.06307

1.000

-6.1811

6.2317

4

2.7750

2.06307

1.000

-3.4314

8.9814

1

-1.4960

2.06307

1.000

-7.7025

4.7104

2

-.0253

2.06307

1.000

-6.2317

6.1811

4

2.7497

2.06307

1.000

-3.4567

8.9561

-8.3630
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4

magB_slc7

1

2

3

4

magB_slc8

1

2

3

4

1

-4.2457

2.06307

.338

-10.4521

1.9607

2

-2.7750

2.06307

1.000

-8.9814

3.4314

3

-2.7497

2.06307

1.000

-8.9561

3.4567

2

2.7587

3.21547

1.000

-6.9145

12.4319

3

1.1879

3.21547

1.000

-8.4853

10.8611

4

3.6151

3.21547

1.000

-6.0581

13.2883

1

-2.7587

3.21547

1.000

-12.4319

6.9145

3

-1.5708

3.21547

1.000

-11.2440

8.1024

4

.8564

3.21547

1.000

-8.8168

10.5296

1

-1.1879

3.21547

1.000

-10.8611

8.4853

2

1.5708

3.21547

1.000

-8.1024

11.2440

4

2.4272

3.21547

1.000

-7.2460

12.1004

1

-3.6151

3.21547

1.000

-13.2883

6.0581

2

-.8564

3.21547

1.000

-10.5296

8.8168

3

-2.4272

3.21547

1.000

-12.1004

7.2460

2

6.8267

5.77138

1.000

-10.5356

24.1889

3

1.4031

5.77138

1.000

-15.9591

18.7654

4

8.6303

5.77138

.926

-8.7320

25.9925

1

-6.8267

5.77138

1.000

-24.1889

10.5356

3

-5.4235

5.77138

1.000

-22.7858

11.9387

4

1.8036

5.77138

1.000

-15.5586

19.1659

1

-1.4031

5.77138

1.000

-18.7654

15.9591

2

5.4235

5.77138

1.000

-11.9387

22.7858

4

7.2271

5.77138

1.000

-10.1351

24.5894

1

-8.6303

5.77138

.926

-25.9925

8.7320

2

-1.8036

5.77138

1.000

-19.1659

15.5586

3

-7.2271

5.77138

1.000

-24.5894

10.1351

Table 2. Post hoc multiple comparisons for diastolic |β| of 16 month old mdx and WT mice.

Group1,2,3, and 4 are WT-LC, WT-NC, mdx-LC, and mdx-NC respectively. MagB, |β|. Slc1 is
base. Slc8 is apex. *, p < 0.05 level. Bonferroni correction. Most differences exist in the slc3 of
group 4, indicating abnormal |β| manifest closer to base than apex.
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Table 3. Post Hoc Multiple Comparisons of |β| in 3 month old mice
Bonferroni
95% Confidence Interval

Mean Difference
Dependent Variable

(I) group

(J) group

magB_slc1

1

2

-1.1000

2.97694

1.000

-10.0556

7.8556

3

.3200

2.97694

1.000

-8.6356

9.2756

4

2.4000

2.97694

1.000

-6.5556

11.3556

1

1.1000

2.97694

1.000

-7.8556

10.0556

3

1.4200

2.97694

1.000

-7.5356

10.3756

4

3.5000

2.97694

1.000

-5.4556

12.4556

1

-.3200

2.97694

1.000

-9.2756

8.6356

2

-1.4200

2.97694

1.000

-10.3756

7.5356

4

2.0800

2.97694

1.000

-6.8756

11.0356

1

-2.4000

2.97694

1.000

-11.3556

6.5556

2

-3.5000

2.97694

1.000

-12.4556

5.4556

3

-2.0800

2.97694

1.000

-11.0356

6.8756

2

-.6400

3.36391

1.000

-10.7598

9.4798

3

2.0400

3.36391

1.000

-8.0798

12.1598

4

3.7400

3.36391

1.000

-6.3798

13.8598

1

.6400

3.36391

1.000

-9.4798

10.7598

3

2.6800

3.36391

1.000

-7.4398

12.7998

4

4.3800

3.36391

1.000

-5.7398

14.4998

1

-2.0400

3.36391

1.000

-12.1598

8.0798

2

-2.6800

3.36391

1.000

-12.7998

7.4398

4

1.7000

3.36391

1.000

-8.4198

11.8198

1

-3.7400

3.36391

1.000

-13.8598

6.3798

2

-4.3800

3.36391

1.000

-14.4998

5.7398

3

-1.7000

3.36391

1.000

-11.8198

8.4198

2

.0600

3.60697

1.000

-10.7910

10.9110

3

2.1800

3.60697

1.000

-8.6710

13.0310

4

6.1800

3.60697

.636

-4.6710

17.0310

1

-.0600

3.60697

1.000

-10.9110

10.7910

3

2.1200

3.60697

1.000

-8.7310

12.9710

4

6.1200

3.60697

.655

-4.7310

16.9710

1

-2.1800

3.60697

1.000

-13.0310

8.6710

2

-2.1200

3.60697

1.000

-12.9710

8.7310

2

3

4

magB_slc2

1

2

3

4

magB_slc3

1

2

3

(I-J)

Std. Error
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Sig.

Lower Bound

Upper Bound

4

magB_slc4

1

2

3

4

magB_slc5

1

2

3

4

magB_slc6

1

2

3

4

4

4.0000

3.60697

1.000

-6.8510

14.8510

1

-6.1800

3.60697

.636

-17.0310

4.6710

2

-6.1200

3.60697

.655

-16.9710

4.7310

3

-4.0000

3.60697

1.000

-14.8510

6.8510

2

.1200

3.07448

1.000

-9.1290

9.3690

3

4.0600

3.07448

1.000

-5.1890

13.3090

4

7.4600

3.07448

.165

-1.7890

16.7090

1

-.1200

3.07448

1.000

-9.3690

9.1290

3

3.9400

3.07448

1.000

-5.3090

13.1890

4

7.3400

3.07448

.178

-1.9090

16.5890

1

-4.0600

3.07448

1.000

-13.3090

5.1890

2

-3.9400

3.07448

1.000

-13.1890

5.3090

4

3.4000

3.07448

1.000

-5.8490

12.6490

1

-7.4600

3.07448

.165

-16.7090

1.7890

2

-7.3400

3.07448

.178

-16.5890

1.9090

3

-3.4000

3.07448

1.000

-12.6490

5.8490

2

-1.0200

3.33267

1.000

-11.0458

9.0058

3

2.5000

3.33267

1.000

-7.5258

12.5258

4

5.6200

3.33267

.667

-4.4058

15.6458

1

1.0200

3.33267

1.000

-9.0058

11.0458

3

3.5200

3.33267

1.000

-6.5058

13.5458

4

6.6400

3.33267

.382

-3.3858

16.6658

1

-2.5000

3.33267

1.000

-12.5258

7.5258

2

-3.5200

3.33267

1.000

-13.5458

6.5058

4

3.1200

3.33267

1.000

-6.9058

13.1458

1

-5.6200

3.33267

.667

-15.6458

4.4058

2

-6.6400

3.33267

.382

-16.6658

3.3858

3

-3.1200

3.33267

1.000

-13.1458

6.9058

2

-.3800

3.73493

1.000

-11.6159

10.8559

3

2.8400

3.73493

1.000

-8.3959

14.0759

4

4.8800

3.73493

1.000

-6.3559

16.1159

1

.3800

3.73493

1.000

-10.8559

11.6159

3

3.2200

3.73493

1.000

-8.0159

14.4559

4

5.2600

3.73493

1.000

-5.9759

16.4959

1

-2.8400

3.73493

1.000

-14.0759

8.3959

2

-3.2200

3.73493

1.000

-14.4559

8.0159

4

2.0400

3.73493

1.000

-9.1959

13.2759

1

-4.8800

3.73493

1.000

-16.1159

6.3559
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magB_slc7

1

2

3

4

2

-5.2600

3.73493

1.000

-16.4959

5.9759

3

-2.0400

3.73493

1.000

-13.2759

9.1959

2

-.2000

3.96679

1.000

-12.1334

11.7334

3

1.8000

3.96679

1.000

-10.1334

13.7334

4

.6800

3.96679

1.000

-11.2534

12.6134

1

.2000

3.96679

1.000

-11.7334

12.1334

3

2.0000

3.96679

1.000

-9.9334

13.9334

4

.8800

3.96679

1.000

-11.0534

12.8134

1

-1.8000

3.96679

1.000

-13.7334

10.1334

2

-2.0000

3.96679

1.000

-13.9334

9.9334

4

-1.1200

3.96679

1.000

-13.0534

10.8134

1

-.6800

3.96679

1.000

-12.6134

11.2534

2

-.8800

3.96679

1.000

-12.8134

11.0534

3

1.1200

3.96679

1.000

-10.8134

13.0534

Table 3 Post hoc multiple comparisons for diastolic |β| of 3 month old mdx and WT mice
showing no significance.
Group1,2,3, and 4 are WT-LC, WT-NC, mdx-LC, and mdx-NC respectively. MagB, |β|. Slc1 is
base. Slc7 is apex. No significance was found among all comparison.

Speculation: Might low gravity ameliorate dystrophy?
In the Chapter 4, we raised the point that higher stress within certain muscles might
explain the regional heterogeneity of dystrophy (e.g., severe at heart base but not apex; severe in
calf but not forearm). If genetic therapy could not break limitations on gene size and achieve
stable transfection, relocating DMD patients to low gravity environments might reduce muscle
stress and ameliorate the dystrophy. Furthermore, low gravity affects normal human health due
to the redistribution of circulation pressure and decrease muscle/skeleton tension (Smith, McCoy
et al. 2012). Lower limb muscles atrophy was observed among astronauts to the greatest extent,
with the calf muscles being most affected and most difficult to target with exercise
countermeasures (Lester, Standley et al. 2013). Similarly, the most obvious pathological sign of
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DMD patients is the pseudo-hypertrophic calf muscle, indicating the calf muscle are sensitive to
stress, both in space and on the Earth. In fact, DMD patients on the Earth and astronauts in orbits
show complimentary loss of muscle fiber types. Specifically, DMD patients lose fast fibers
rather than slow fibers (Webster, Silberstein et al. 1988), while astronauts lose slow fibers rather
than fast fiber (Riley, Bain et al. 2002). I hypothesize that dystrophin is part of stress sensing
pathway and signals to reduce astronauts’ slow fibers in response to the lower load. When
dystrophin is missing, the presumed stress sensing pathway might over-react to the normal stress
on the earth and signal to reduce fast fibers in DMD. Since it is unknown how exactly lowgravity changes circulation/muscle/skeleton 14, how dystrophin-null animals adapt low-gravity
environment may shed lights on such mechanism and bring better solutions to counter atrophy in
space missions. The hypothetical mechanical sensing and protective mechanism of dystrophin
would be critical for extraplanetary exploration, when we would need to fine-tune human body
to adapt different gravities.
Sources of funding:
American Heart Association 12PRE9310044 (Cheng), R01 AR056223 (Wickline)

14

“The exact cellular and biochemical events that produce these losses of mass and strength are not as well
understood.” NASA 2013. Effect of Prolonged Space Flight on Human Skeletal Muscle (Biopsy)
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